

**Memorial Sloan-Kettering Cancer Center and
Weill Cornell Medical College
*Curriculum vitae and Bibliography***

Date of preparation: January 13, 2025

A. GENERAL INFORMATION

1. Name: Dennis S. Chi
2. Office address, telephone, fax: Memorial Sloan Kettering Cancer Center
Gynecology Service, Department of Surgery
1275 York Avenue
New York, NY 10065
3. Email: chid@mskcc.org
4. Citizenship: USA

B. EDUCATIONAL BACKGROUND

- | | | |
|------|---|-----------|
| B.A. | Columbia University –
Columbia College, New York, NY | 1982-1986 |
| M.D. | New York University School
of Medicine, New York, NY | 1986-1990 |

C. PROFESSIONAL POSITIONS AND EMPLOYMENT

1. Post-doctoral training

- | | | |
|------------|--|-----------|
| Residency | New York University School of Medicine
New York, NY | 1990-1994 |
| Fellowship | Memorial Sloan-Kettering Cancer Center
New York, NY | 1994-1997 |

2. Academic positions

- | | | |
|---------------------|--|-----------|
| Clinical Instructor | Dept of Obstetrics and Gynecology
Weill Cornell Medical College
New York, NY | 1997-2003 |
|---------------------|--|-----------|

Assistant Member	Gynecology Service, Dept of Surgery Memorial Sloan-Kettering Cancer Center New York, NY	2001-2005
Assistant Professor	Dept of Obstetrics and Gynecology Weill Cornell Medical College New York, NY	2003-2006
Associate Member	Gynecology Service, Dept of Surgery Memorial Sloan-Kettering Cancer Center New York, NY	2005-2010
Associate Professor	Dept of Obstetrics and Gynecology Weill Cornell Medical College New York, NY	2006-2011
Member	Gynecology Service, Dept of Surgery Memorial Sloan-Kettering Cancer Center New York, NY	2010-Present
Professor	Dept of Obstetrics and Gynecology Weill Cornell Medical College New York, NY	2011-Present

3. Hospital positions

Assistant Surgeon	Gynecology Service, Dept of Surgery Memorial Sloan-Kettering Cancer Center New York, NY	1997-2001
Director, Resident and Medical Student Education	Gynecology Service, Dept of Surgery Memorial Sloan-Kettering Cancer Center New York, NY	1997-2002
Physician Leader, GYN Inpatient Unit	Memorial Sloan-Kettering Cancer Center New York, NY	1999-2002
Assistant Attending Surgeon	Gynecology Service, Dept of Surgery Memorial Sloan-Kettering Cancer Center New York, NY	2001-2005
Co-Director, Pelvic Reconstructive Surgery	Department of Surgery Memorial Sloan-Kettering Cancer Center New York, NY	2001-2014

Director, Fellowship Program	Gynecology Service Memorial Sloan-Kettering Cancer Center New York, NY	2002-2014
Associate Attending Surgeon	Gynecology Service, Dept of Surgery Memorial Sloan-Kettering Cancer Center New York, NY	2005-2010
Attending Surgeon	Gynecology Service, Dept of Surgery Memorial Sloan-Kettering Cancer Center New York, NY	2010-Present
Deputy Chief	Gynecology Service, Dept. of Surgery Memorial Sloan-Kettering Cancer Center New York, NY	2011-Present
Section Head	Ovarian Cancer Surgery Section Gynecology Service, Dept. of Surgery Memorial Sloan-Kettering Cancer Center New York, NY	2014-Present
Surgical Director	MSK-CATCH Program Gynecology Service, Dept. of Surgery Memorial Sloan-Kettering Cancer Center New York, NY	2021-Present

4. Other Employment

N/A

D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

1. Licensure

a.	State	Number	Date of issue	Date of last Registration
	New York	187616	1990	April 2025

b. If no license:

(1) Do you have a temporary certificate?

(2) Have you passed the examination for foreign medical school graduates?

c. DEA number: BC3338894

2. Board Certification

American Board of Obstetrics & Gynecology	# 940153	11/20/98
ABOG Gynecologic Oncology	# 940153O	04/18/01

3. Malpractice insurance

Do you have Malpractice Insurance? **Yes**

Name of Provider: **MSK Insurance US, Inc.**

Premiums paid by: (choose one)

a. self	b. group (name)	c. institution (Memorial Sloan-Kettering Cancer Center)
---------	-----------------	--

E. PROFESSIONAL MEMBERSHIPS

Member	American Medical Association	1991-Present
Fellow	American Cancer Society	1996-Present
Member	Society of Surgical Oncology	1996-Present
Member	Society of Memorial Gynecologic Oncologists	1997-Present
Member	American Society of Clinical Oncology	1997-Present
Member	Association of Professors of Gynecology & Obstetrics	1999-2010
Fellow	American College of Obstetricians & Gynecologists	1999-Present
Member	Society of Laparoendoscopic Surgeons	2000-2014
Fellow	New York Obstetrical Society	2001-2017
Member	Society of Gynecologic Oncologists	2002-Present
Member	Society of Gynecologic Surgeons	2002-2014
Member	Korean American Medical Association	2004-Present
Member	International Gynecologic Cancer Society	2004-Present
Member	Association of Korean American Medical Graduates	2004-Present
Fellow	American College of Surgeons	2004-Present
Member	Korean American Medical Physicians Association	2006-Present
Fellow	American Gynecological Obstetrical Society	2010-2014
Fellow	Society of Pelvic Surgeons	2010-Present

F. HONORS AND AWARDS

Magna Cum Laude, Columbia College	1986
Phi Beta Kappa, Columbia College	1986
Trainee Investigator Award, American Federation for Clinical Research	1994
NYU School of Medicine Ob/Gyn Resident Teacher-of-the-Year Award	1991
Berlex Oncology Foundation Award	1997
The Stanley Zinberg, Teaching Award, NYU Downtown Medical Center	2000
Tibotec Award for Research in Gynecologic Oncology	2004
Best Doctors in America	2005
Weill Cornell Medical College Clinical and Translational Science Center (CTSC) Award	2008
NY Times Super Doctors	2008-Present
NY Metro Area Top Doctors	2011-Present
America's Top Doctors	2012-Present
America's Top Doctors for Cancer	2012-Present
NY Magazine's Best Doctors	2012-Present
Newsweek's America's Top Doctors for Cancer	2015
Korean American Medical Association Physician Leader Award	2015
Cycle for Survival Award	2016
Ronald O. Perelman Chair in Gynecologic Surgery	2018
The Bellevue Obstetrical and Gynecological Society Distinguished Alumnus Award	2019
SGO Lifetime Achievement Award	2024

G. INSTITUTIONAL/HOSPITAL AFFILIATION

1. Primary Hospital Affiliation: **Memorial Hospital for Cancer and Allied Diseases**
2. Other Hospital Affiliations: Weill Cornell Medical College
3. Other Institutional Affiliations: N/A

H. EMPLOYMENT STATUS

1. Name of Current Employer(s): **Memorial Sloan-Kettering Cancer Center**
2. Employment Status (choose one): **Full-time**

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT

1. Teaching/Mentoring

Teach preoperative, intraoperative, and postoperative management of patients with gynecologic malignancies to fellows, residents, and medical students. Fellow comes to my outpatient clinic once per week. Mentor 1997 – Present

fellows on 10 – 15 clinical research projects yearly.

2. Clinical care

I see outpatients two days per week and I operate three days per week. 1997-Present

3. Administrative duties

Director, Fellowship Program, Gynecology Service	2002-2014
Co-Director, Pelvic Reconstruction Surgery Group, Dept. of Surgery	2001-2014
Physician Leader, M10 Inpatient Unit	1999-2002
Deputy Chief, Gynecology Service	2011-Present
Head, Ovarian Cancer Surgery Section	2014-Present
Member, Surgical Promotions Committee	2014-Present
Member, Surgical Finance Committee	2019-2022
Surgical Director, MSK-CATCH Program	2021-Present

4. Research

Research mainly focuses on outcomes after surgery for gynecologic malignancies. 1997-Present

	Current Percent Effort (%)	Does the activity involve WMC students or researchers? (Y/N)	Does the activity involve MSK trainees or researchers? (Y/N)
Teaching/Mentoring	20	N	N
Clinical Care	60	N	N
Administration	5	N	N
Research	15	N	N
TOTAL: 100%			

J. RESEARCH AWARDS/SUPPORT/CLINICAL TRIALS

Tibotec Award for Research in Gynecologic Oncology 2004
Role: PI \$60,000

Empire Clinical Research Investigator Program (ECRIP) Award: 2005
A Prospective Study of Quality of Life in Patients
Undergoing Total Pelvic Exenteration
Role: Co-PI \$50,000

Weill Cornell Medical College Clinical and Translational 2008
Science Center (CTSC) Award: Electronic Patient-Reported Outcomes in
Patients Recovering from Major Gynecologic Cancer Surgery: Measuring
Quality of Life and Pain

Role: Co-PI \$50,000

Acute Normovolemic Hemodilution in Patients Undergoing
Cytoreductive Surgery for Advanced Ovarian Cancer 2011
Role: PI \$45,000

A Phase II Randomized Study: Outcomes after Secondary 2012
Cytoreductive Surgery with or without Carboplatin Hyperthermic
Intraperitoneal Chemotherapy (HIPEC) followed by
Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive
Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Role: PI \$250,000

Gail Baird Foundation Award: Intraoperative Detection of 2013
Lesions Using PET Probe During Secondary Cytoreductive
Surgery for Recurrent Ovarian Cancer: A Pilot Study
Role: PI \$100,000

Radiology Developmental Project Fund Award for 2013
Multiparametric Imaging and Genomics: Can We Predict Clinical
Outcome in Patients with Recurrent Cervical Cancer Undergoing
Pelvic Exenteration?
Role: Co-PI \$50,000

Management of Patients with Persistent and Recurrent Mucinous 2013
Ovarian Cancer
Role: PI \$100,000

Department of Surgery Faculty Research Award for 2013
Pharmacokinetics and Pharmacodynamics of Intraoperative
Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with
Carboplatin in Patients with Platinum-Sensitive Recurrent Ovarian
Cancer
Role: Co-PI \$80,000

A Phase II Trial of Aldara as Adjuvant Therapy in Completely 2013
Resected Pagets Disease of the Vulva
Role: PI \$185,000

MSKCC Society Award: Benchmarking Intra-tumor Heterogeneity in 2013
in Ovarian Cancer: Linking Invivo Imaging Phenotypes with Histology
and Genomics
Role: Co-PI \$180,000

Cycle for Survival Award for Ovarian Cancer Research 2016
Role: PI \$1,000,000

MSK MIND Award: Integration of Radiomic Analysis into the Multi-Modal Profiling of High-Grade Serous Ovarian Cancer Role: Co-PI \$200,000	2019
OCRA Award: Profiling Co-Evolution of Ovarian Cancer and its Immune Microenvironment Role: Co-PI \$267,000	2020
DOD Award: Dissecting the impact of mutational processes on therapeutic response in ovarian cancer Role: Co-PI	2020
Speer Foundation Grant for Gynecologic Cancer Research Role: PI \$1,090,000	2006-Present

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

Other Activities:

Gynecology Service Representative, Surgical Quality Assurance Committee, Memorial Sloan Kettering Cancer Center	1999-2002
Scientific Program Director, Twenty-fifth annual meeting of the Society of Memorial Gynecologic Oncologists	2002
Secretary-Treasurer, Society of Memorial Gynecologic Oncologists	2002-2005
Program Chairman, 4th Annual International Conference on Ovarian Cancer	2003
Member, Executive Council, Metropolitan Gynecologic Cancer Society	2003 - 2004
Oral Board Examiner, American Board of Obstetrics & Gynecology	2004- Present
President, Metropolitan Gynecologic Cancer Society	2004-2005
Member, Program Committee, 36th Annual Meeting of the Society of Gynecologic Oncologists	2005
Course Director, Postgraduate Course on Upper Abdominal and Pelvic Debulking Techniques: Modern Reconstructive Surgery, 36th Annual Meeting of the Society of Gynecologic Oncologists	2005
Scientific Program Chairman, 23rd Annual Convention, Korean-American Medical Association	2005

Editorial Board, Gynecologic Oncology	2005-2008
Member, Ovarian Cancer Committee, Gynecologic Oncology Group	2005-2010
President, Society of Memorial Gynecologic Oncologists	2006-2007
Member, Education Committee, Society of Gynecologic Oncologists	2006-2009
Member, Clinical Outcomes Program, Society of Gynecologic Oncologists	2006-2009
Course Director, Postgraduate Course On Techniques of Surgical Resection and Reconstruction for Advanced and Recurrent Gynecologic Malignancies, 38th Annual Meeting of the Society of Gynecologic Oncologists	2007
Editorial Board, The Oncologist	2007- Present
Section Editor, Gynecologic Oncology, The Oncologist	2007- Present
Member, Board of Governors, NYU School of Medicine	2007- Present
Course Director, Postgraduate Course on Radical Upper Abdominal & Retroperitoneal Resection of Advanced Malignancy, 39th Annual Meeting of the Society of Gynecologic Oncologists	2008
Course Director, International Conference on Total Pelvic Exenteration Comemorating the 60-Year Anniversary of Alexander Brunschwig's Sentinel Report – Achievements and Open Questions, 39th Annual Meeting of the Society of Gynecologic Oncologists	2008
Course Director, Postgraduate Course on The Management of Patients with Platinum-Sensitive Recurrent Ovarian Cancer, 39th Annual Meeting of the Society of Gynecologic Oncologists	2008
Program Chairman, Society of Gynecologic Oncologists 2 nd Annual Summer Meeting	2008
Scientific Program Chairman, 26 th Annual Convention, Korean-American Medical Association	2008
Course Director, Postgraduate Course on Techniques for Resection of Upper Abdominal Disease in Patients with Advanced Malignancy, 40th Annual Meeting of the Society of Gynecologic Oncologists	2009
Course Director, Complex Intestinal, Urinary, and Reproductive Tract Injuries In the Management of Gynecologic Malignancies, 40th Annual	2009

Meeting of the Society of Gynecologic Oncologists

Member, Gynecologic Task Force for the AJCC Cancer Staging Manual, 7 th ed.	2009
Editorial Board, Journal of Oncology	2009 - Present
Oral Board Examiner, Subspecialty Exam in Gynecologic Oncology American Board of Obstetrics & Gynecology	2010 - 2014
Program Chairperson, Pro/Con Debate on Neoadjuvant Chemotherapy vs Primary Debulking, 13 th Biennial Meeting of the International Gynecologic Cancer Society	2010
Member, Nominating Committee, Society of Gynecologic Oncologists	2010 – 2011
Co-Chairman, 1 st GEICO Video Workshop on Surgical Management of Advanced Ovarian Cancer	2011
Co-Chairman, Postgraduate Courses, 42 nd Annual Meeting of the Society of Gynecologic Oncologists	2011
Editorial Board, Journal of Gynecologic Oncology	2011 – Present
Course Director, Techniques for Surgical Debulking. SGO 43rd Annual Meeting on Women's Cancer, Austin, TX.	3/26/12
Course Director, Contemporary Management of Ovarian Cancer SGO 44th Annual Meeting on Women's Cancer. Los Angeles, CA	3/11/13
Council Member, NY OB Society	2014 - 2017
Advisory Board Member, TEAL (Tell Every Amazing Lady) About Ovarian Cancer	2015 - Present
Board Member, Society of Gynecologic Oncology	2016 - 2019
Editorial Committee, Revista de Ginecologia Oncologica	2016 - Present
Editorial Board, Journal of Gynecologic Surgery	2020 – Present
Advisory Board Member, Ovarcome	2021 – Present
Course Director, Out-Of-The Box Gynecologic Cancer Surgery. The IRCAD, Strasbourg, France	2021, 2022
Member, Program Committee, IGCS 2023 Global Annual Meeting	2023

Invited National/International Lectures (Selected):

Surgical Treatment of Uterine Cancer. International Symposium on Women Oncology, Rio de Janeiro, Brazil.	08/25/00
Surgical Treatment of Ovarian Cancer. International Symposium on Women Oncology, Rio de Janeiro, Brazil.	08/25/00
Radical Surgical Resection and High-dose Intraoperative Radiation Therapy in Patients with Recurrent Gynecological Cancer. State of the Art in the Treatment of Cervical Cancer Symposium, Rome, Italy.	11/30/00
Management of Lymph Node Positive Patients. State of the Art in the Treatment of Cervical Cancer Symposium, Rome, Italy.	12/01/00
Patients with suboptimal ovarian cancer should be given neoadjuvant chemotherapy before surgery. Controversies in the Management of Gynecologic Malignancies 3, Washington, DC.	12/05/02
Approaching the acute abdomen in female patients. American College of Surgeons' 89th Annual Clinical Congress, Chicago, IL	10/20/03
New approaches in the surgical management of ovarian cancer. Keynote Speaker. 1st Annual International Conference on Ovarian Cancer, Morioka, Japan.	06/12/04
New approaches in the surgical management of ovarian cancer. American College of Surgeons' 90th Annual Clinical Congress, New Orleans, LA.	10/11/04
New approaches in the surgical management of ovarian cancer. 8th Annual J. Goodrich Clark Memorial Lecture. Johns Hopkins University Medical Center, Baltimore, MD.	02/3/05
Screening for ovarian cancer. Surgical management of ovarian cancer. 1st Annual International Gynecologic Pathologic Conference. Savannah, GA.	04/13/05
Secondary surgical cytoreduction. 6th Annual International Ovarian Cancer Conference. New York, NY.	11/03/05
Neoadjuvant Chemotherapy for Advanced Ovarian Cancer – Debate 37 th Annual Meeting of the Society of Gynecologic Oncologists. Palm Springs, CA.	03/24/06

Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent platinum-sensitive epithelial ovarian carcinoma. 21st Annual Meeting of the Korean Society of Gynecologic Oncology and Colposcopy. Gyeongju, Korea.	04/21/06
Surgical management of ovarian cancer at Memorial Sloan-Kettering Cancer Center. Radical pelvic resections for recurrent uterine Malignancies. 3rd KIRAMS-MSKCC Joint Conference. Seoul, Korea.	04/27/06
Cytoreductive surgery for ovarian cancer. Keynote speaker. Residents Research Day. St. Vincent Hospital, Indianapolis, IN.	06/14/06
Extensive upper abdominal surgery for advanced ovarian cancer. 1st International Conference on Ovarian Cancer: State of the Art and Future Directions. Crete, Greece.	06/27/06
New approaches in the surgical management of ovarian cancer. 3rd Annual Diana Bittner Memorial Lecture. Yorktowne Hospital. York, PA.	09/21/06
Management of the incidental ovarian masses. American College of Surgeons 92nd Annual Clinical Congress, Chicago, IL.	10/10/06
Update on Cytoreductive Surgery for Ovarian Cancer. 2nd Annual C. Thomas Griffiths, MD Lecture in Gynecologic Oncology. Massachusetts General Hospital, Boston MA	11/8/06
Neoadjuvant Chemotherapy vs Primary Surgery for advanced ovarian cancer: debate. 7th Annual International Ovarian Cancer Conference. Houston, TX.	12/01/06
Aggressive cytoreduction for ovarian cancer. 2nd Annual Symposium on Regional Cancer Therapies. San Juan, Puerto Rico.	02/24/07
Justification for upper abdominal cytoreduction. 38th Annual Meeting of the Society of Gynecologic Oncologists. San Diego, CA.	03/03/07
The use of minimally invasive surgery in ovarian cancer. Keynote speaker. The 12 th Seoul International Symposiumo on Recent Advances in Gynecologic Malignancies. Seoul, Korea.	10/04/07
Incorporation of extensive upper abdominal surgical techniques improves survival in advanced ovarian cancer. Keynote speaker. The 93 rd Semi-annual meeting of the Korean Society of Obstetrics and Gynecology. Seoul, Korea.	10/05/07
Neoadjuvant chemotherapy or Radical cytoreduction for patients with advanced ovarian cancer – SGO Fight Night Debate. 39 th Annual Meeting of	3/10/08

the Society of Gynecologic Oncologists. Tampa, FL.

Surgery for ovarian cancer. Keynote speaker. 7 th Annual Meeting of the Argentine Association of Gynecologic Oncologists. Rosario, Argentina.	5/9/08
Current status of cytoreductive surgery for patients with advanced ovarian, tubal and peritoneal carcinomas. Keynote speaker. 44 th Annual Congress of the Japan Society of Gynecologic Oncology. Nagoya, Japan.	7/17/08
Gynecology – Case-based Review. 94 th RSNA Scientific Assembly and Annual Meeting. Chicago, IL.	12/4/08
Ovarian cancer debulking. Keynote speaker. Inaugural Joint Conference of The Australia/New Zealand Gynaecologic Oncology Group and The Australian Society of Gynaecologic Oncologists. Noosa, Australia.	4/2/09
Surgery for recurrent cervical cancer. State of the Science Meeting on Cervical Cancer. Sponsored by the NCI, NCRI, GCIG. Manchester, England.	6/18/09
Debate: Neoadjuvant Chemotherapy vs Primary Cytoreduction. Gynecologic Oncology Group Symposium. Baltimore, MD.	7/16/09
Ovarian Team – A Multidisciplinary Approach with Advanced Cytoreductive Surgery. 4 th Annual International Symposium on Peritoneal Carcinomatosis. Regensburg, Germany.	9/18/09
What About Intraperitoneal Chemotherapy. 4 th Annual International Symposium on Peritoneal Carcinomatosis. Regensburg, Germany.	9/18/09
Debate: Surgery or Chemo – Which One First? 8 th Annual International Conference on Ovarian Cancer. New York, NY.	9/25/09
Debate: Management of Advanced Ovarian Cancer: Primary cytoreduction vs Neoadjuvant Chemotherapy. 2 nd Annual MD Anderson International Conference in Gynecologic Oncology. Houston, TX.	2/18/10
Debate: Patients with stage IIIC-IV ovarian carcinoma should receive neoadjuvant chemotherapy prior to any attempted bulk reduction. 7 th International Symposium on Ovarian Cancer and Other Gynecologic Malignancies. New York, NY	3/27/10
Taking it to the Limit _ Maximally Invasive Surgery in Ovarian Cancer. 10 th Annual Continuing Professional Development Meeting of the Society of Gynecologic Oncology of Canada. Montreal, Canada.	4/30/10
Ultra-Radical Surgery in Advanced Ovarian Cancer. 60 th Royal College of	9/14/10

Obstetricians and Gynaecologists Study Group - Gynaecological Cancers.
London, England.

Teaching bowel surgery. 13th Biennial Meeting of the International
Gynecologic Cancer Society. Prague, Czech Republic. 10/23/10

Video assisted thoracoscopy in ovarian cancer. How to integrate this tool
in the surgical management. 1st GEICO Video Workshop on Surgical
Management of Advanced Ovarian Cancer. Valencia, Spain. 3/3/11

Dealing with bulky disease in the upper abdomen. 1st GEICO Video
Workshop on Surgical Management of Advanced Ovarian Cancer.
Valencia, Spain. 3/3/11

Sparing Fertility Surgery in Gynecological Cancer: Cervical, Uterine
and Ovarian Cancers. 6th International Meeting of Obstetrics and Gynecology.
Vina del Mar, Chile. 4/28/11

Sparing Fertility Surgery in Cervical Cancer. 6th International Meeting of
Obstetrics and Gynecology. Vina del Mar, Chile. 4/28/11

Feasibility of primary cytoreduction: when and how? 6th International
Meeting of Obstetrics and Gynecology. Vina del Mar, Chile. 4/28/11

Future of Surgery in Gynecologic Oncology. 6th International Meeting of
Obstetrics and Gynecology. Vina del Mar, Chile. 4/29/11

Surgical Management of Recurrent Endometrial Cancer. 6th International
Meeting of Obstetrics and Gynecology. Vina del Mar, Chile. 4/29/11

Supraradical Surgery vs Neoadjuvant Chemotherapy. 4th European
Symposium on Ovarian Cancer. Reims, France. 6/24/11

Techniques Used for Maximal Debulking of Ovarian Cancer, American
College of Surgeons 97th Annual Clinical Congress, San Francisco, CA 10/24/11

Cytoreductive Surgery: Diaphragm, Thorax, & VATS. Advanced Course in
Cytoreductive Surgery for Ovarian Cancer & Gynecologic Surface
Malignancies, Orange, CA 11/4/11

Cytoreductive Surgery Program Development. Advanced Course in
Cytoreductive Surgery for Ovarian Cancer & Gynecologic Surface
Malignancies, Orange, CA 11/4/11

Techniques of Upper Abdominal Resection. British Gynaecological
Cancer Society Autumn Meeting, Birmingham, England 11/17/11

Paradigm Shift in Surgery for Advanced Ovarian Cancer. British Gynaecological Cancer Society Autumn Meeting, Birmingham, England	11/18/11
Debate: Recurrent Ovarian Cancer: Should Surgery Remain the Ideal Option?: Pro, 3 rd MD Anderson International Conference in Gynecologic Oncology, Madrid, Spain	3/15/12
Fertility Preserving Surgery for Cervical Cancer. Visiting Professorship for Residents Day, Christiana Care Health System, Newark, Delaware	4/4/12
Debate: Patients with Newly Diagnosed Advanced Ovarian Carcinoma, Unless Surgery is Contraindicated Medically, Should Undergo an Aggressive Attempt at Surgical Bulk Reduction Before Receiving Any Systemic Treatment (Chemotherapy or Biologic Therapy): Pro. Great Debates and Updates in Gynecological Malignancies. New York, NY	4/28/12
Outside the Envelope Surgery. British Surgical Gynecologic Oncology Group Meeting. Gateshead, England.	5/4/12
Secondary Cytoreduction in Ovarian Cancer. 14th Biennial Meeting of the International Gynecologic Cancer Society. Vancouver, Canada	10/13/12
Role of Primary Debulking Surgery. Surgical Anatomy Course in Ovarian Cancer: Comparing Opinions of Different Institutions. European School of Abdomino-pelvic surgery in Gynecologic Oncology. Milan, Italy.	11/8/12
Nomogram for Predicting 5-Year Disease-Specific Mortality after Primary Surgery for Epithelial Ovarian Cancer. 3 rd Tropé-Kolstad Meeting Ovarian Cancer: Controversies in Management. Oslo, Norway	12/7/12
Does Intraperitoneal Therapy for Ovarian Cancer Have a Future? 3 rd Tropé-Kolstad Meeting. Ovarian Cancer: Controversies in Management. Oslo, Norway	12/7/12
Primary Surgical Management of Advanced Ovarian Cancer. University of Miami Ob/Gyn Grand Rounds. Miami, Fla	2/13/13
Primary Surgical Management of Advanced Ovarian Cancer Epithelial Ovarian Cancer. Keynote Speaker at the 3 rd Congress of the Polish Society of Gynecologic Oncologists. Bialowieza, Poland	5/17/13
Primary Cytoreductive Surgery and Upper Abdominal Resection in Epithelial Ovarian Cancer. Fudan University Shanghai Cancer Center Annual CME Meeting on Gynecologic Cancers. Shanghai, China	9/8/13

Heated Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies. Korean American Medical Physicians of New York (KAMPANY) fall Scientific Forum. Long Island, NY	9/26/13
Cytoreductive Surgery: Diaphragm, Thorax, and VATS Advanced Course in Cytoreductive Surgery for Ovarian Cancer and Peritoneal Surface Malignancies: Radical Pelvic and Upper Abdominal Procedures with Cadaver Dissection. Laguna Beach, CA	10/18/13
Oncologic Results of Extended Pelvic Resection. 4th Annual MD Anderson International Meeting in Gynecologic Oncology: Emerging Therapies in Gynecologic Cancer. Madrid, Spain.	2/19/14
Colorectal Resection in Advanced Ovarian Cancer. 4th Annual MD Anderson International Meeting in Gynecologic Oncology: Emerging Therapies in Gynecologic Cancer. Madrid, Spain.	2/20/14
Role of HIPEC therapy: A new frontier or therapy with no future? 4th Annual MD Anderson International Meeting in Gynecologic Oncology: Emerging Therapies in Gynecologic Cancer. Madrid, Spain.	2/20/14
The Extraganza Operation for Advanced Ovarian Cancer: Is it Worthwhile?" Ob/Gyn Grand Rounds. Beth Israel Medical Center. New York, NY	5/14/14
Challenging the Dogma in Ovarian Cancer Treatment. Discussant Gynecologic Cancer Oral Abstract Session. 50 th Annual Meeting of ASCO. Chicago, Illinois	5/31/14
Surgical Advances in Gynaecologic Cancers. Keynote Lecture. Annual Scientific Meeting of the British Gynecologic Cancer Society. London, England	7/11/14
Debate: Delayed vs Upfront Debulking in Advanced Ovarian Cancer. Annual Scientific Meeting of the British Gynecologic Cancer Society. London, England	7/11/14
Optimal Management of Advanced Ovarian Cancer: Upfront Surgery Remains the Best Option. Ovarian Cancer: A Comprehensive Symposium on Medical and Surgical Management. Medellin, Colombia	9/11/14
Debate: Role of Routine Lymphadenectomy in Advanced Disease: Pro. Ovarian Cancer: A Comprehensive Symposium on Medical and Surgical Management. Medellin, Colombia	9/12/14
What is the Best Sequence in the Treatment of Advanced Resectable Ovarian	10/25/14

Cancer? V International Gynecology Oncology Congress. Sao Paulo, Brazil	
Are Peritonectomy and Hyperthermic Chemotherapy Recommended in Intraoperative Therapy as Routine Treatment? V International Gynecology Oncology Congress. Sao Paulo, Brazil	10/25/14
The Role of Rescue in Recurrent Ovarian Cancer. V International Gynecology Oncology Congress. Sao Paulo, Brazil	10/25/14
Use of imaging and tumor markers to predict suboptimal cytoreduction Winter GYN Symposium at NRG Oncology Semi-Annual. San Diego, CA.	2/5/15
The “Kaizen” Approach to Surgery for Advanced Ovarian Cancer. A Joint Symposium of KAMA, KMA, KHA. Seoul, Korea	8/7/15
The Impact of Aggressive Surgery on Survival in Advanced Ovarian Cancer 4 th Biennial Meeting of the Asian Society of Gynecologic Oncology (ASGO). Seoul, Korea	11/12/15
Primary Cytoreduction vs Neoadjuvant Chemotherapy for Ovarian Cancer 4 th Biennial Meeting of the Asian Society of Gynecologic Oncology (ASGO). Seoul, Korea	11/12/15
Finding the Limit of Aggressive Surgery in Newly Diagnosed Patients with Advanced Ovarian Cancer. Russian Society of Clinical Oncology (RUSSCO) and American Society of Clinical Oncology (ASCO) joint annual conference. Moscow, Russia	3/25/16
Endometriosis Associated Ovarian Cancer. Endometriosis Foundation of America 2016 annual medical conference. New York, NY	4/19/16
The “Kaizen” Approach to Surgery for Advanced Ovarian Cancer. 2 nd Annual John J. Mikuta Lecture. University of Pennsylvania. Philadelphia, PA	5/12/16
Early Knife Saves Life. Neoadjuvant Chemotherapy Education Session ASCO Annual Meeting. Chicago, Illinois	6/6/16
The “Kaizen” Approach to Surgery for Advanced Ovarian Cancer. 58 th Annual Meeting of the Japan Society of Gynecologic Oncology. Yonago, Japan	7/9/16
Right Upper Quadrant and Thoracic Surgery. Gynecologic Oncology Fellows’ Advanced Course in Cytoreductive Surgery for Ovarian Cancer. Irvine, CA	11/4/16
The “Kaizen” Approach to Surgery for Advanced Ovarian Cancer. 56 th Annual Isador Forman Lecture. Temple University. Philadelphia, PA	12/14/16

Effect on the Surgical Training and Overall Outcomes: the MSKCC Experience. Conference of Radical Surgery in Advanced Ovarian Cancer: “Old” but still the Gold Standard. European Institute of Oncology. Milan, Italy.	1/30/17
Preoperative Work Up for PDS. Conference of Radical Surgery in Advanced Ovarian Cancer: “Old” but Still the Gold Standard. European Institute of Oncology. Milan, Italy.	1/31/17
Initial Evaluation and Preoperative Work-Up for Patients who Present with Presumed Advanced Ovarian Carcinoma. University of Alabama Comprehensive Cancer Center Research Seminar. Birmingham, Alabama.	5/25/17
The “Kaizen” Approach to Primary Debulking Surgery for Advanced Ovarian Cancer. Brittany Waldrep Endowed Lectureship. University of Alabama. Birmingham, Alabama.	5/26/17
Primary Cytoreduction in Ovarian Cancer. Topics in Gynecologic Oncology Symposium. Cancun, Mexico	9/12/17
HIPEC in Ovarian Cancer. Topics in Gynecologic Oncology Symposium. Cancun, Mexico	9/12/17
Diaphragm and Thoracic Surgery. Advanced Course in Cytoreductive Surgery for Ovarian Cancer and Peritoneal Surface Malignancies. Laguna Beach, CA	10/19/17
Intrathoracic Cytoreduction. Master of Disaster with Live-OP 2018. Essen, Germany	2/15/18
The “Kaizen” Approach to Surgery for Advanced Ovarian Cancer. Keynote Symposium Lecture. 29 th Annual Philip J. DiSaia Society Ob/Gyn Symposium And 36 th Annual UCI Residents Paper Day. Irvine CA	5/4/18
Surgery Above the Diaphragm: Why, When and How. Cytoreductive Surgery for Ovarian Cancer Course. Coventry, England	5/16/18
Initial Evaluation, Work-Up, and Management Algorithm of Advanced Ovarian Cancer. Cytoreductive Surgery for Ovarian Cancer Course. Coventry, England	5/16/18
Timing of Surgery in Peritoneal Carcinomatosis from Ovarian Carcinoma PSOGI Workshop on Peritoneal Surface Malignancies. Paris, France	9/11/18
Diaphragm and Thoracic Surgery. Advanced Course in Cytoreductive Surgery for Gynecologic Cancer. Laguna Beach, CA	5/3/19
Selection of Patients for Reoperative Surgery. Mid-Atlantic Ovarian Cancer	6/15/19

Symposium. Bethesda, MD

SOC-1, GOG213, DESKTOP III: Why is GOG 213 Negative? Master of Disaster Annual Conference. Essen, Germany	9/4/20
PDS for Primary Management of Advanced Ovarian Cancer. 2020 IGCS Annual Global Meeting.	9/11/20
The Kaizen Approach to Primary Ovarian Cancer Cytoreduction Surgery Ovarian Cancer – Quest for a Better Tomorrow. Association of Gynaecologic Oncologists of India Webinar.	2/20/21
Removal of Porta Hepatis Carcinomatosis. Advanced Gynecologic Oncology Surgery: A Multidisciplinary Out-of-the Box Approach. The IRCAD, Strasbourg, France	4/13/21
Management of Extensive Peritoneal Disease of the Small Bowel and Mesentery Advanced Gynecologic Oncology Surgery: A Multidisciplinary Out-of-the Box Approach. The IRCAD, Strasbourg, France	4/14/21
How would you stratify advanced stage (III-IV) patients to upfront vs interval debulking surgery? Kazakhstan Cancer Society Centeast webinar series: Hard Talk on Serous Ovarian Cancer.	4/28/21
Do you apply the ERAS principles in the perioperative care? Kazakhstan Cancer Society Centeast webinar series: Hard Talk on Serous Ovarian Cancer.	4/28/21
The Evolution of Debulking Surgery in Advanced Ovarian Cancer. 6th APOLLO symposium. Shanghai, China.	8/14/21
How to Select Patients for Neoadjuvant Chemotherapy. Master of Disaster Annual Conference. Essen, Germany	9/3/21
The Evolving Role of Surgery in Ovarian Cancer. First International Surgical Oncology Symposium. National University Cancer Institute, Singapore.	9/4/21
The “Kaizen” Approach to Primary Surgical Cytoreduction for Advanced Ovarian Cancer. Symmonds Endowed Lectureship. The Mayo Clinic. Rochester, Minnesota.	10/29/21
I Favor Primary Cytoreduction Followed by Chemotherapy for Advanced Ovarian Cancer Over the Opposite Sequence. Annual IX Gynecology-Oncology Congress. Sao Paulo, Brazil	11/13/21
Salvage surgery for recurrent ovarian cancer: should be offered routinely. Annual IX Gynecology-Oncology Congress. Sao Paulo, Brazil	11/13/21

“R0” Surgery in Newly Diagnosed Advanced Ovarian Cancer. "MDT Live Show"Conference ONLINE. Beijing, China	12/6/21
Liver Exposure & Mobilization, Liver Resection, Porta Hepatis, Celiac Trunk SGO Postgraduate Course: Debulking and Deliver. Phoenix, AZ	3/4/22
Management of Extensive Peritoneal Disease of Small Bowel and Mesentery. IRCAD Gynaecologic cancer surgery course. Strasbourg, France	4/11/22
Liver Exposure & Mobilization, Liver Resection, Porta Hepatis, Celiac Trunk. Advanced Course in Cytoreductive Surgery for Ovarian Cancer. Oslo, Norway	5/4/22
Personalized Medicine in Patient Selection for Ovarian Cancer Surgery in the Primary Setting. 11 th Annual Trope Meeting. Oslo, Norway	5/6/22
MSKCC Algorithm for Determining PDS vs NACT in the Primary Management of Advanced Ovarian Cancer. Global Hospital Exchange on World Ovarian Cancer Day Webinar. Shanxi, China	5/7/22
Diaphragm and Thoracic Surgery. Advanced Course in Cytoreductive Surgery for Gynecologic Cancer. Irvine, CA	5/13/22
Surgical Strategies for Stage IV Ovarian Cancer. 1 st Singhealth Peritoneal Surface Oncology Conference. Singapore	8/26/22
How to Select Patients for either PDS or NACT. Master of Disaster Disaster Annual Conference. Essen, Germany	9/1/22
“R0” Surgery in Newly Diagnosed Advanced Ovarian Cancer. "MDT Live Show"Conference ONLINE. Beijing, China	10/28/22
The Kaizen Approach to Primary Ovarian Cancer Cytoreduction Surgery Ovarian Cancer. Annual Meeting on Gynecologic Oncology. Suzhou, China	11/5/22
The Learning Curve for Ovarian Cancer Cytoreduction. Barretos International Course: Advanced Ovarian Cancer. Barretos, Brazil	11/18/22
Video Assisted Thoracic Surgery and Intrathoracic Cytoreduction. Barretos International Course: Advanced Ovarian Cancer. Barretos, Brazil	11/19/22
Debate: MIS vs Open Surgery in Interval Cytoreduction. SGO Annual Meeting On Women’s Cancer. Tampa, FLA	3/26/23
“R0” Surgery in Newly Diagnosed Advanced Ovarian Cancer. Gynecological Oncology International Advances. Guangdong, China	4/7/23

Diaphragm and Thoracic Surgery. Advanced Course in Cytoreductive Surgery for Gynecologic Cancer. Irvine, CA	5/4/22
Current State-of-the Art of Cytoreductive Surgery in Ovarian Cancer Advanced Ovarian Cancer Surgery: Moving Towards Complete Cytoreduction. Lisbon, Portugal	6/16/23
Intrathoracic Cytoreduction at Primary Debulking Surgery for Advanced Ovarian Cancer. Advanced Ovarian Cancer Surgery: Moving Towards Complete Cytoreduction. Lisbon, Portugal	6/16/23
Porta Hepatis and Liver Resections. Advanced Ovarian Cancer Surgery: Moving Towards Complete Cytoreduction. Lisbon, Portugal	6/16/23
Irresectable Disease -What is it? Advanced Ovarian Cancer Surgery: Moving Towards Complete Cytoreduction. Lisbon, Portugal	6/16/23
The Incorporation of Upper Abdominal and Thoracic Surgery as Part of PDS For Advanced Ovarian Cancer: The MSKCC Story. 2 nd West Lake Summit of International Gynecologic Oncology Conference. China.	8/4/23
Secondary Cytoreduction. XIV National Congerence of Gynecologic Oncology. Buenos Aires, Argentina	8/10/23
Is there a precise indication for HIPEC? XIV National Congerence of Gynecologic Oncology. Buenos Aires, Argentina	8/10/23
Intrathoracic Cytoreduction in Primary Surgery. XIV National Congerence of Gynecologic Oncology. Buenos Aires, Argentina	8/11/23
Management of Thoracic Disease. Master of Disaster Disaster Annual Conference. Essen, Germany	9/7/23
MSKCC Algorithm for Triaging Patients to Either PDS or NACT. IGCS 2023 Global Annual Meeting	11/7/23
I Favor PDS Followed by Chemotherapy Over NACT/IDS Followed by Chemotherapy. X International Congress in Gynecology-Oncology. Sao Paulo, Brazil	3/23/24
Secondary Cytoreduction for Recurrent Ovarian Cancer – I Favor this Approach in Eligible Patients. X International Congress in Gynecologic-Oncology. Sao Paulo, Brazil	3/23/24
Beyond the Abdomen: Diahragm, VATS, & Cardiophrenic Nodes	5/21/24

Advanced Course in Cytoreductive Surgery for Gynecologic Peritoneal Malignancies. Oslo, Norway

Secondary Cytoreductive Surgery & Beyond
Advanced Course in Cytoreductive Surgery for Gynecologic Peritoneal Malignancies. Oslo, Norway

5/22/24

L. BIBLIOGRAPHY

Peer-Reviewed Publications:

1. Lowenwirt IP, **Chi DS**, Handwerker SM. Nonfatal venous air embolism during cesarean section: A case report and review of the literature. *Obstet Gynecol Surv* 1994;49:72-76.
2. Handwerker SM, Altura BT, **Chi DS**, Altura BM. Serum ionized magnesium levels during intravenous magnesium therapy of preeclamptic women. *Acta Obstet Gynecol Scand* 1995;74:517-519.
3. **Chi DS**, Barakat RR, Curtin JP. Laparoscopic management of adnexal masses in women with a history of non-gynecologic malignancy. *Obstet Gynecol* 1995;86:964-968.
4. **Chi DS**, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. *Gynecol Oncol* 1997; 65:493-498.
5. **Chi DS**, Fong Y, Venkatraman ES, Barakat RR. Hepatic resection for metastatic gynecologic carcinomas. *Gynecol Oncol* 1997;66:45-51.
6. **Chi DS**, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in stage IV endometrial carcinoma. *Gynecol Oncol* 1997; 67:56-60.
7. Rubin SC, Randall TC, Armstrong KA, **Chi DS**, Hoskins WJ. Ten-year follow-up of ovarian cancer patients having negative second-look laparotomy after platinum-based clinical outcomes and predictors of recurrence. *Obstet Gynecol* 1999;93:21-24.
8. Gemignani ML, **Chi DS**, Gurin CC, Curtin JP, Barakat RR. Splenectomy in recurrent epithelial ovarian cancer. *Gynecol Oncol* 1999; 72:407-410.
9. Abu-Rustum NR, **Chi DS**, Wiatrowska BA, Guiter G, Saigo PE, Barakat. The accuracy of frozen-section diagnosis in metastatic breast and colorectal carcinoma to the adnexa. *Gynecol Oncol* 1999;73(1):102-105.

10. **Chi DS**, Waltzman RJ, Barakat RR, Spriggs DR. Primary intravenous paclitaxel and platinum chemotherapy for high-risk stage I epithelial ovarian carcinoma. *Eur J Gynecol Cancer* 1999;20(4):277-80.
11. Boyd J, Sonoda Y, Federici MG, Bogomolny F, Rhei E, Maresco DL, Saigo PE, Almadrones LA, Barakat RR, Brown CL, **Chi DS**, Curtin JP, Poynor EA, Hoskins WJ. Clinicopathologic features of BRCA linked and sporadic ovarian cancer. *JAMA* 2000;283(17):2260-5.
12. **Chi DS**, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA 125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. *Gynecol Oncol* 2000;77(2):227-231.
13. Husain A, Curtin J, Brown C, **Chi D**, Hoskins W, Poynor E, Alektiar K, Barakat R. Continent urinary diversion in patients undergoing exenterative or palliative procedures for recurrent gynecologic cancers. *Gynecol Oncol* 2000;78(2):208-11.
14. Husain A, **Chi DS**, Prasad M, Abu-Rustum N, Barakat RR, Brown CL, Poynor EA, Hoskins WJ, Curtin JP. The role of laparoscopy in second-look evaluations for ovarian cancer. *Gynecol Oncol* 2001;80:44-4.
15. Hensley ML, Lebeau D, Leon LF, Venkatraman E, Waltzman R, Sabbatini P, Almadrones L, **Chi D**, Spriggs MD. Identification of risk factors for requiring transfusion during front line chemotherapy for ovarian cancer. *Gynecol Oncol* 2001; 81:485-489.
16. Gemignani ML, Alektiar K, Leitao M, Mychalczak B, **Chi DS**, Barakat RR, Curtin JP. Radical surgical resection and combined high dose intra-operative radiation therapy (IORT) in patients with recurrent gynecologic cancers. *Int J Radiation Oncology Biol Phys* 2001;50(3):687-694.
17. **Chi DS**, Liu JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ. Identification of prognostic factors in advanced epithelial ovarian carcinoma. *Gynecol Oncol* 2001; 82:532-537.
18. Hensley ML, Hoppe B, Leon L, Sabbatini P, Aghajanian C, **Chi D**, Spriggs DR. The costs and efficacy of liposomal doxorubicin in platinum refractory ovarian cancer in heavily pre-treated patients. *Gynecol Oncol* 2001;82:464-469.
19. **Chi D**, Jones W, Barakat R, O'Keefe K, Hoskins W, Lewis J. The benefit of a special elective gynecologic oncology program for obstetrics and gynecology residents. *Eur J Gynecol Cancer* 2001; 4:266-268.
20. Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman E, **Chi D**, Bergman A, Hricak H. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. *Radiology* 2002 ;223(2):495-9.

21. **Chi DS**, Temkin SM, Abu-Rustum NR, Sabbatini P, Blumgart LH. Major hepatectomy at interval debulking for stage IV ovarian carcinoma: A case report. *Gynecol Oncol* 2002; 87:138- 142.
22. Pothuri B, **Chi DS**, Reid T, Aghajanian C, Venkatraman E, Alektiar K, Bilski M, Barakat RR. Craniotomy for central nervous system metastases in epithelial ovarian carcinoma. *Gynecol Oncol* 2002;87:133-137.
23. Awtrey C, Marshall D, Soslow R, **Chi DS**. Clinically inapparent invasive vulvar carcinoma in an area of persistent paget's disease: a case report. *Gynecol Oncol* 2003;88(3):440-3.
24. Robson M, Hensley M, Barakat R, Greene J, Kelly B, Brown C, **Chi D**, Poynor E, Carter J, Offit K. Impact of Risk-reducing Oophorectomy on Quality of Life in Women at Risk for Ovarian Cancer. *Gynecol Oncol* 2003;89:281-287.
25. Pothuri B, Vaidya A, Aghajanian C, Venkatraman E, Barakat RR, **Chi DS**. Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. *Gynecol Oncol* 2003;89:306-313.
26. Abu-Rustum NR, **Chi DS**, Sonoda Y, DiClemente MJ, Bekker G, Gemignani M, Poynor E, Brown C, Barakat RR. Transperitoneal laparoscopic pelvic and paraaortic lymph node dissection using the argon beam coagulator and monopolar instruments: an 8-year study and description of technique. *Gynecol Oncol* 2003;89(3):504-13.
27. Menell JH, **Chi DS**, Hann LE, Hedvig H. The use of MRI in the diagnosis and management of a bulky cervical carcinoma. *Gynecol Oncol* 2003;89(3):517-21.
28. Abu-Rustum NR, Sonoda Y, **Chi DS**, Teoman H, Dizon D, Venkatraman E, Barakat RR. The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. *Gynecol Oncol* 2003;90(2):431-4.
29. Leitaio MM, Sonoda Y, Brennan MF, Barakat RR, **Chi DS**. Incidence of lymph node metastases in leiomyosarcoma of the uterus. *Gynecol Oncol* 2003;91(1):209-12.
30. Yoon SS, Jarnagin WR, DeMatteo RP, Fong Y, Barakat RR, Blumgart LH, **Chi DS**. Resection of Recurrent Ovarian or Fallopian Tube Carcinoma Involving the Liver. *Gynecol Oncol* 2003;91(2):383-388.
31. Abu-Rustum NR, Gemignani M, Moore K, Sonoda Y, Venkatraman E, Brown C, Poynor E, **Chi DS**, Barakat RR. Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon beam coagulator: Pilot data and comparison to laparotomy. *Gynecol Oncol* 2003;91(2):402-409.

32. Funt SA, Hricak H, Abu-Rustum N, Mazumdar M, Felderman H, **Chi DS**. Recurrent ovarian cancer: role of CT scan in patient management. *Am J Roentgenol* 2004;182:393-398.
33. Abu-Rustum NR, Rhee EH, **Chi DS**, Sonoda Y, Gemignani M, Barakat RR. Subcutaneous tumor implantation after laparoscopic procedures in women with malignant disease. *Obstet Gynecol* 2004;103:480-487.
34. Carter J, **Chi DS**, Abu-Rustum N, Brown, CL, McCreath W, Barakat RR. Total pelvic exenteration: a retrospective clinical needs assessment. *Psychooncology* 2004;13:125-131.
35. Prasad M, Hensley ML, Ben-Porat L, Hoppe B, Aghajanian C, **Chi DS**, Spriggs DR. Use of gemcitabine or topotecan as second-line therapy or greater for relapsed ovarian cancer: response, survival, and costs of treatment. *Gynecol Oncol* 2004;93:223-228.
36. Nouriani M, Bahador A, Berek JS, Cheng JP, **Chi DS**, Cilby WA, Del Priore G, Dodson MK, Duggan BD, Gershenson DM, Lentz SE, Munderspach LI, Penson RT, Robinson WR, Rodriguez M, Yu MC, Zempolich K, Dubeau L. Detection of residual, sub-clinical, ovarian carcinoma following completion of adjuvant chemotherapy. *Clin Cancer Res* 2004;10:2681-2686.
37. Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, Dizon D, O'Flaherty C, Bloss J, **Chi D**, Spriggs D. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II trial. *Clin Cancer Res* 2004;10:2962-2967.
38. Bochner BH, McCreath WA, Aubey JJ, Levine DA, Barakat RR, Abu-Rustum N, Wong D, **Chi DS**. Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation. *Gynecol Oncol* 2004;94:140-146.
39. **Chi DS**, Abu-Rustum NR, Sonoda Y, Chen SW, Flores RM, Downey R, Aghajanian C, Barakat RR. The benefit of video-assisted thoracoscopic surgery (VATS) prior to abdominal exploration in the management of patients with suspected epithelial ovarian cancer and moderate to large pleural effusions. *Gynecol Oncol* 2004;94:307-311.
40. **Chi DS**, Franklin CC, Levine DA, Akselrod F, Sabbaini P, Jarnagin WR, Dematteo R, Poynor EA, Abu-Rustum N, Barakat RR. Improved optimal cytoreduction rates for stage IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal carcinoma: a change in surgical approach. *Gynecol Oncol* 2004;94:650-654.
41. Leitao MM, Kardos S, Barakat RR, **Chi DS**. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. *Gynecol Oncol* 2004;95:181-188.

42. Pothuri B, Meyer L, Gerardi M, Barakat RR, **Chi DS**. Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma. *Gynecol Oncol* 2004;95:193-195.
43. Stier EA, Krown S, **Chi DS**, Brown CL, Chiao EY, Lin O. Anal dysplasia in HIV-infected women with cervical and vulvar dysplasia. *J Lower Genital Tract Dis* 2004;8:272-275.
44. **Chi DS**, Abu-Rustum N, Sonoda Y, Awtrey CS, Hummer A, Venkatraman E, Franklin CC, Hamilton F, Gemignani ML, Barakat RR. Ten-year experience with laparoscopy on a gynecologic oncology service: an analysis of risk factors for complications and conversion to laparotomy. *Am J Obstet Gynecol* 2004;191:1138-1145.
45. Pothuri B, Guirguis A, Gerdes H, Barakat RR, **Chi DS**. Utilization of colorectal stents for palliation of large bowel obstruction due to recurrent gynecologic cancer. *Gynecol Oncol* 2004;95:513-517.
46. Sonoda Y, Abu-Rustum NR, Gemignani ML, **Chi DS**, Brown CL, Poynor EA, Barakat RR. A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible? *Gynecol Oncol* 2004;95:534-538.
47. Eitan R, Saenz CC, Venkatraman ES, Hann L, Bach A, Gretz E, Barakat RR, **Chi DS**. Pilot study prospectively evaluating the use of the measurement of preoperative sonographic endometrial thickness in postmenopausal patients with endometrial cancer. *Menopause* 2005;12(1):27-30.
48. Rezk Y, Sheinfeld J, **Chi DS**. Prolonged survival following salvage surgery for chemorefractory ovarian immature teratoma: a case report and a review of the literature. *Gynecol Oncol* 2005;96(3):883-887.
49. Eitan R, Levine DA, Abu-Rustum NA, Sonoda Y, Huh JN, Franklin CC, Barakat RR, **Chi DS**. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. *Cancer* 2005;103:1397-401.
50. Carter J, Rowland K, **Chi DS**, Brown C, Abu-Rustum N, Castiel M, Barakat R. Gynecologic cancer treatment and the impact of cancer-related infertility *Gynecol Oncol* 2005;97(1):90-95.
51. Salomon C, Tornos C, **Chi DS**. Borderline endometrioid tumor arising in a paratubal cyst: case report. *Gynecol Oncol* 2005;97(1):263-5.
52. Alektiar KM, Venkatraman E, **Chi DS**, Barakat RR. Intravaginal brachytherapy alone for intermediate risk endometrial cancer. *Int J Radiat Oncol Biol Phys* 2005;62(1):111-117.

53. **Chi DS**, Abu-Rustum NR, Sonoda Y, Ivy J, Rhee E, Moore K, Levine DA, Barakat RR. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. *Am J Obstet Gynecol* 2005;192(5):1614-9.
54. Haddad L, Amsterdam A, **Chi DS**. Celiac disease presenting as a paraneoplastic syndrome in a patient with synchronous endometrial and ovarian cancers. *Gynecol Oncol* 2005;97(2):704-6.
55. Amendola M, Hricak H, Mitchell D, **Chi DS**, Snyder B, Gatsonis C. Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: results of an intergroup protocol ACRIN 6651/GOG protocol 183. *J Clin Oncol* 2005;23:7454-7459.
56. Abu-Rustum NR, Richard S, Wilton A, Lev G, Sonoda Y, Hensley ML, Gemignani M, Barakat RR, **Chi DS**. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival. *Gynecol Oncol* 2005;99(2):320-6.
57. Hricak H, Gatsonis C, **Chi DS**, Amendola M, Brandt K, Schwartz LH, Koelliker S, Siegelman E, Brown JJ, McGhee R, Iyer R, Vitellas KM, Mitchell DG. Role of imaging for pretreatment evaluation of invasive cervical cancer: results of an intergroup protocol: ACRIN 6551/GOG 183. *J Clin Oncol* 2005;23:9329-9337.
58. Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Barakat RR, **Chi DS**. Morbidity of rectosigmoid resection and anastomosis in high risk patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. *Gynecol Oncol* 2005;99:608-614.
59. Tchabo NE, Grobmeyer SR, Jarnagin WR, **Chi DS**. Conservative management of pneumatosis intestinalis. *Gynecol Oncol* 2005;99:782-784.
60. Mourton SM, **Chi DS**, Sonoda Y, Alektiar KM, Venkatraman ES, Barakat RR, Abu-Rustum NR. Mesorectal lymph node involvement and prognostic implications at total pelvic exenteration for gynecologic malignancies *Gynecol Oncol* 2006;100(3):533-6.
61. Juretzka M, Abu-Rustum NR, Sonoda Y, Jarnagin WR, Flores RM, Barakat RR, **Chi DS**. Full thickness diaphragmatic resection for stage IV ovarian carcinoma using the EndoGIA stapling device with diaphragmatic reconstruction using a gortex graft: a case report and review of the literature. *Gynecol Oncol* 2006;100:618-20.
62. Leiser AL, Anderson SE, Chuai S, Olshen AB, **Chi DS**, Soslow RA. Apoptotic and cell cycle regulatory markers in uterine smooth muscle neoplasms. *Gynecol Oncol* 2006;101:86-91.
63. **Chi DS**, McCaughty K, Schwabenbauer S, Huh J, Hummer A, Venkatraman E, Aghajanian C, Diaz J, Sonoda Y, Abu-Rustum N, Barakat RR. Guidelines and Selection

Criteria for Secondary Cytoreductive Surgery in Patients with Recurrent Platinum Sensitive Epithelial Ovarian Carcinoma. *Cancer* 2006;106(9):1933-9.

64. **Chi DS**, Abu-Rustum NR, Sonoda Y, Im B, Jhamb N, D'Angelica M, Rim M, Barakat RR. Laparoscopic and hand-assisted laparoscopic splenectomy for recurrent and persistent ovarian cancer. *Gynecol Oncol* 2006; 101:224-227.
65. Juretzka M, Crawford CL, Lee C, Schuman S, **Chi DS**, Sonoda Y, Barakat RR, Abu-Rustum NR. Laparoscopic management of adnexal masses in women with a history of nongynecologic malignancy. *Gynecol Oncol* 2006;101:327-330.
66. McCreath WA, Abu-Rustum NR, Venkatraman ES, Caceres A, Bier R, Huh J, Cho J, Barakat RR, **Chi DS**. Identification of Prognostic Factors after Positive Second Look Surgery in Epithelial Ovarian Carcinoma. *Gynecol Oncol* 2006;102:8-14.
67. Anderson SE, Nonaka D, Chuai S, Olshen AB, **Chi D**, Sabbatini P, Soslow RA. P53, epidermal growth factor, and platelet derived growth factor in uterine leiomyosarcoma and leiomyomas. *Int J Gynecol Cancer* 2006;16(2):849-53.
68. Maluf FC, Leiser AL, Aghajanian C, Sabbatini P, Pezzulli S, **Chi DS**, Levenback C, Loh E, Spriggs D. Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. *Int J Gynecol Cancer* 2006;16(3):1165-71
69. Hensley ML, Correa DD, Thaler H, Wilton A, Venkatraman E, Sabbatini P, **Chi DS**, Spriggs D, Aghajanian C. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian, primary peritoneal and fallopian tube cancer: pathologic complete response and longitudinal assessment of impact on cognitive function. *Gynecol Oncol* 2006;102(2):270-7.
70. Eitan R, Soslow R, Kauff N, Barakat RR, **Chi DS**. The Significance of Cytological Mesothelial Atypia Diagnosed from Peritoneal Washings Performed During Risk-Reducing Salpingo-Oophorectomy. *Gynecol Oncol* 2006;102(2):315-8.
71. Awtrey CS, Cadungog MG, Leitao MM, Alektiar KM, Aghajanian C, Hummer AJ, BarakatRR, **Chi DS**. Surgical Resection of Recurrent Endometrial Carcinoma. *Gynecol Oncol* 2006;102:480-488.
72. dos Santos LA, Modica I, Flores R, D'Angelica M, Aghajanian C, **Chi DS**, Abu-Rustum NR. En bloc diaphragm resection with partial pneumonectomy for recurrent ovarian cancer: a case report. *Gynecol Oncol* 2006;102:598-598.
73. Abu-Rustum NR, Restivo A, Ivy J, Soslow R, Sabbatini P, Sonoda Y, Barakat RR, **Chi DS**. Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. *Gynecol Oncol* 2006;103:31-34.

74. Sovak MA, Alektiar K, Ishill N, Abu-Rustum N, Barakat R, Dupont J, Hensley ML, **Chi DS**, Sabbatini P, Spriggs DR, Aghajanian. Paclitaxel and carboplatin in the adjuvant treatment of patients with stage III and IV endometrial cancer: a retrospective review. *Gynecol Oncol* 2006;103:451-457.
75. **Chi DS**, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma? *Gynecol Oncol* 2006;103:559-564.
76. Abu-Rustum NR, Alektiar K, Iasonos A, Sonoda Y, Aghajanian C, **Chi DS**, Barakat RR. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: an 12-year experience at Memorial Sloan-Kettering Cancer Center. *Gynecol Oncol* 2006;103:714-718.
77. Abu-Rustum NR, Sonoda Y, Black D, **Chi DS**, Barakat RR. Cystoscopic temporary ureteral catheterization during radical vaginal and abdominal trachelectomy. *Gynecol Oncol* 2006;103:729-731.
78. Abu-Rustum NR, Sonoda Y, Black D, Levine DA, **Chi DS**, Barakat RR. Fertility-sparing radical abdominal hemihysterectomy for cervical carcinoma: technique and review of the literature. *Gynecol Oncol* 2006;103:807-813.
79. Eisenhauer EL, D'Angelica MI, Abu-Rustum NR, Sonoda Y, Barakat RR, **Chi DS**. Incidence and management of pleural effusions after diaphragm stripping or resection for advanced mullerian cancer. *Gynecol Oncol* 2006;103:871-877.
80. Bristow RE, **Chi DS**. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. *Gynecol Oncol*. 2006;103(3):1070-6.
81. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian CA, Jarnagin WR, DeMatteo RP, D'Angelica MI, Barakat RR, **Chi DS**. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stage IIIC-IV epithelial ovarian cancer. *Gynecol Oncol* 2006;103:1083-1090.
82. Juretzka MM, Barakat RR, **Chi DS**, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. *Gynecol Oncol*. 2007;104(3):670-4.
83. Bristow RE, Eisenhauer EL, Santillan A, **Chi DS**. Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction. *Gynecol Oncol*. 2007;104(2):480-90.

84. Ferguson SE, Gerald W, Barakat R, **Chi DS**, Soslow RA. Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults. *Am J Surg Pathol.* 2007;31(3):382-389.
85. Mourton SM, Sonoda Y, Abu-Rustum NR, Bochner BH, Barakat RR, **Chi DS**. Resection of recurrent cervical cancer after total pelvic exenteration. *Int. J Gynecol Cancer* 2007;17(1):137-40.
86. Juretzka MM, Abu-Rustum NR, Sonoda Y, Downey RJ, Flores RM, Park BJ, Hensley ML, Barakat RR, **Chi DS**. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. *Gynecol Oncol.* 2007;104(3):670-4.
87. Black D, Tornos C, Soslow RA, Awtrey CS, Barakat RR, **Chi DS**. The outcomes of patients with positive margins after excision for intraepithelial Paget's disease of the vulva. *Gynecol Oncol.* 2007;104(3):547-50.
88. Kebria M, Black D, Borelli D, Hensley M, **Chi DS**. Primary retroperitoneal lymphangioleiomyomatosis in a postmenopausal woman: a case report and review of the literature. *Int J Gynecol Cancer.* 2007;17(2):528-32.
89. Leiser AL, Maluf FC, **Chi DS**, Sabbatini P, Hensley ML, Schwartz L, Venkatraman E, Spriggs D, Aghajanian C. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. *Int J Gynecol Cancer.* 2007;17(2):379-86.
90. Barakat RR, Lev G, Hummer AJ, Sonoda Y, **Chi DS**, Alektiar KM, Abu-Rustum NR. Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches. *Gynecol Oncol.* 2007;105(1):150-6.
91. Leiser A, **Chi DS**, Ishill N, Tew B. Carcinosarcoma of the ovary treated with platinum and taxane – the Memorial Sloan-Kettering Cancer Center experience. *Gynecol Oncol.* 2007;105(3):657-61.
92. Husain A, Akhurst T, Larson S, Alektiar K, Barakat RR, **Chi DS**. A prospective study of the accuracy of (18)Fluorodeoxyglucose positron emission tomography ((18)FDG PET) in identifying sites of metastasis prior to pelvic exenteration. *Gynecol Oncol.* 2007;106(1):177-80.
93. Hensley ML, Dizon D, Derosa F, Venkatraman E, Sabbatini P, **Chi DS**, Dupont J, Colevas AD, Spriggs D, Aghajanian C. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. *Invest New Drugs* 2007;25(4):335-41.
94. Black D, Iasonos A, Ahmed H, **Chi DS**, Barakat RR, Abu-Rustum NR. Effect of venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer *Gynecol Oncol.* 2007;107(1):66-70.

95. Aletti GD, Santillan A, Eisenhauer EL, Aletti G, Podratz KC, Bristow RE, **Chi DS**, Cliby WA. A new frontier for quality care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model *Gynecol Oncol*. 2007;107(1):99-106.
96. Anthony T, Baron T, Mercadante S, Green S, **Chi D**, Cunningham J, Herbst A, Smart E, Krouse RS. Report of the Clinical Protocol Committee: Development of Randomized Trials for Malignant Bowel Obstruction. *J Pain Symptom Manage* 2007;34:S49-S59.
97. Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, Huh J, Barakat RR, **Chi DS**. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. *Gynecol Oncol*. 2007;106(2):381-7.
98. Eisenhauer EL, Wypych KA, Mehrara BJ, Lawson C, **Chi DS**, Barakat RR, Abu-Rustum NR. Comparing surgical outcomes in obese women undergoing laparotomy, laparoscopy, or laparotomy with panniculectomy for the staging of uterine malignancy. *Ann Surg Oncol*. 2007;14(8):2384-91.
99. **Chi DS**, Ramirez PT, Teitcher J, Mironov S, Sarasohn D, Iyer R, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Brown CL, Hricak H, Barakat RR. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. *J Clin Oncol* 2007;25:4946-4951.
100. Sonoda Y, **Chi DS**, Carter J, Barakat RR, Abu-Rustum NR. Initial experience with Dargent's operation: the radical vaginal trachelectomy. *Gynecol Oncol* 2008;108(1):214-9.
101. **Chi DS**, Palayekar MJ, Sonoda Y, Abu-Rustum NR, Awtrey CS, Huh J, Barakat RR, Kattan MW. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. *Gynecol Oncol* 2008 ;108(1):191-4.
102. Eisenhauer EL, Sonoda Y, Levine DA, Abu-Rustum NR, Gemignani ML, Sabbatini PJ, Barakat RR, **Chi DS**. Platinum-resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched case comparison to patients with epithelial ovarian carcinoma. *Am J Obstet Gynecol* 2008;198:213.e1-213.e7.
103. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, **Chi DS**. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. *Gynecol Oncol* 2008;108:276-281.

104. Zivanovic O, Eisenhauer EL, Qin CZ, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, **Chi DS**. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. *Gynecol Oncol* 2008;108:287-292.
105. **Chi DS**, Barakat RR, Palayekar MJ, Levine DA, Sonoda Y, Alektiar K, Brown CL, Abu-Rustum NR. The Incidence of Pelvic Lymph Node Metastasis by FIGO Staging for Patients with Adequately Surgically Staged Endometrial Adenocarcinoma of Endometrioid Histology. *Int J Gynecol Cancer*. 2008;18(2):269-73.
106. Caceres A, Zhou Q, Iasonos A, Gerdes H, **Chi DS**, Barakat RR. Colorectal stents for palliation of large bowel obstruction in recurrent gynecologic cancer: an updated series. *Gynecol Oncol*. 2008;108(3):482-5.
107. Abu-Rustum NR, Iasonos A, Zhou Q, Oke E, Soslow RA, Alektiar KM, **Chi DS**, Barakat RR. Is there a therapeutic benefit to regional lymphadenectomy in the treatment of endometrioid uterine corpus cancer? *Am J Obstet Gynecol*. 2008;198(4):457.e1-5; discussion 457.e5-6.
108. Black D, Levine DA, Nicoll L, Chou JF, Iasonos A, Brown CL, Sonoda Y, **Chi DS**, Leitao MM, Abu-Rustum NR, Ferguson SE, Barakat RR. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in epithelial ovarian cancer. *Gynecol Oncol*. 2008;109(1):39-42.
109. Thomas M, Wright J, Leiser A, **Chi DS**, Mutch D, Podratz KC, Dowdy SC. Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era. *Gynecol Oncol* 2008;109:335-339.
110. Zhang J, Mironov S, Hricak H, Ishill N, Moskowitz CS, Soslow RA, **Chi DS**. Characterization of adnexal masses using feature analysis at contrast-enhanced helical CT. *J Comput Assist Tomogr*. 2008;32(4):533-40.
111. Akin O, Sala E, Moskowitz CS, Ishill N, Soslow RA, **Chi DS**, Hricak H. Perihepatic metastases from ovarian cancer: accuracy of CT in detection of lesions with and without liver parenchymal invasion. *Radiology*. 2008;248(2):511-7.
112. Caceres A, Mourton SM, Bochner BH, Gerst SR, Liu L, Alektiar KM, Kardos SV, Barakat RR, Boland PJ, **Chi DS**. Extended pelvic resections for recurrent uterine and cervical cancer: out of the box surgery. *Int J Gynecol Cancer*. 2008;18(5):1139-44.
113. Einstein MH, Barakat RR, **Chi DS**, Sonoda Y, Alektiar KM, Hensley ML, Abu-Rustum NR. Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. *Int J Gynecol Cancer*. 2008;18(5):1065-70.

114. Carter J, Sonoda Y, **Chi DS**, Raviv L, Abu-Rustum NR. Radical trachelectomy for cervical cancer: postoperative physical and emotional adjustment issues. *Gynecol Oncol.* 2008;111(1):151-7.
115. Abu-Rustum NR, **Chi DS**, Leitao M, Oke EA, Hensley ML, Alektiar KM, Barakat RR. What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma? *Gynecol Oncol.* 2008;111(1):46-8.
116. Abu-Rustum NR, Neubauer N, Sonoda Y, Park K, Gemignani M, Alektiar K, Tew W, Leitao MM, **Chi DS**, Barakat RR. Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. *Gynecol Oncol.* 2008;111(2):261-4.
117. Diaz JP, Sonoda Y, Leitao MM, Zivanovic O, Brown CL, **Chi DS**, Barakat RR, Abu-Rustum NR. Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. *Gynecol Oncol.* 2008;111(2):255-60.
118. Leitao MM, Kehoe S, Barakat RR, Alektiar K, Gattoc LP, Rabbitt C, **Chi DS**, Soslow RA, Abu-Rustum NR. Accuracy of preoperative endometrial smpling diagnosis of FIGO grade 1 endometrial adenocarcinoma. *Gynecol Oncol.* 2008 ;111(2):244-8.
119. Zivanovic O, Alektiar KM, Sonoda Y, Zhou O, Iasonons A, Tew WP, Diaz JP, **Chi DS**, Barakat RR, Abu-Rustum NR. Treatment patterns of FIGO stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy *Gynecol Oncol.* 2008;111(2):265-70.
120. Zivanovic O, Sonoda Y, Diaz JP, Levine DA, Brown CL, **Chi DS**, Barakat RR, Abu-Rustum NR. The rate of port site metastases after 2251 laparoscopic procedures in women with malignant disease. *Gynecol Oncol.* 2008;111(3):431-7.
121. **Chi DS**, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Leitao MM, Brown CL, Barakat RR. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. *Gynecol Oncol.* 2009;111(1):6-10.
122. Einstein MH, Park KJ, Sonoda Y, Carter J, **Chi DS**, Barakat RR, Abu-Rustum NR. Radical Vaginal Versus Abdominal Trachelectomy for Stage IB1 Cervical Cancer: A Comparison of Surgical & Pathologic Outcomes. *Gynecol Oncol.* 2009;112(1):73-7.
123. Alektiar KM, Makker V, Abu-Rustum NR, Soslow RA, **Chi DS**, Barakat RR, Aghajanian C. Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer. *Gynecol Oncol.* 2009;112(1):142-5.
124. Bristow RE, Puri I, **Chi DS**. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. *Gynecol Oncol.* 2009;112(1):265-74.

125. Kehoe SM, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, D'Angelica M, Jarnagin WR, Barakat RR, **Chi DS**. Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer. *Gynecol Oncol*. 2009;112(3):496-500.
126. Zivanovic O, Leitao Jr MM, Park KJ, Zhao H, Diaz JP, Konner J, Alektiar K, Sonoda Y, **Chi DS**, Barakat RR, Abu-Rustum NR, Aghajanian C. Small cell neuroendocrine carcinoma of the cervix: analysis of survival, recurrence pattern and the impact of platinum-based combination chemotherapy. *Gynecol Oncol*. 2009;112(3):590-3.
127. Leitao MM, Kehoe S, Barakat RR, Alektiar K, Gattoc LP, Rabbitt C, **Chi DS**, Soslow RA, Abu-Rustum NR. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma prior to hysterectomy. *Gynecol Oncol*. 2009;113:105-108.
128. Zivanovic O, Leitao MM, Iasonos A, Jacks LM, Zhou Q, Abu-Rustum NR, Soslow RA, Juretzka MM, **Chi DS**, Barakat RR, Brennan MF, Hensley ML. Stage-Specific Outcomes of Patients With Uterine Leiomyosarcoma: A comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. *J Clin Oncol*. 2009;27(12):2066-72.
129. Matsuo K, Walker LD, **Chi DS**, Rosenshein NB, Im DD. Ultrasonic surgical aspiration for vaginal intraepithelial neoplasia. *Int J Gynaecol Obstet*. 2009 ;105(1):71-3.
130. Abu-Rustum NR, Khoury-Colado F, Pandit-Taskar N, Soslow RA, Dao F, Sonoda Y, Levine DA, Brown CL, **Chi DS**, Barakat RR, Gemignani ML. Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the dilemma of surgical staging. *Gynecol Oncol*. 2009;113:163-160.
131. Kehoe SM, Williams NL, Yakubu R, Levine DA, **Chi DS**, Sabbatini PJ, Aghajanian CA, Barakat RR, Abu-Rustum NR. Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian, tubal and peritoneal malignancies. *Gynecol Oncol*. 2009;113:228-232.
132. **Chi DS**, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Aghajanian C, Guile MW, Bristow RE, Barakat RR. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. *Gynecol Oncol*. 2009;114:26-31.
133. Ferguson SE, Malhotra T, Venkatraman ES, Levine DA, Sonoda Y, **Chi DS**, Barakat RR, Abu-Rustum NR. A randomized trial comparing patient-controlled epidural analgesia (PCEA) to patient-controlled intravenous analgesia (PCA) on postoperative pain control and recovery after major open gynecologic cancer surgery. *Gynecol Oncol*. 2009;114(1):111-6.

134. **Chi DS**, Phaeton R, Miner TJ, Kardos S, Diaz J, Leitao M, Gardner G, Huh J, Tew W, Konner J, Sonoda Y, Abu-Rustum NR, Barakat RR, Jaques DP. A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. *Oncologist*. 2009;14(8):835-9.
135. Schlaerth AC, **Chi DS**, Poynor EA, Barakat RR, Brown CL. Long term survival after fertility sparing surgery for epithelial ovarian cancer. *Int J Gynecol Cancer*. 2009;19(7):1199-204.
136. Bochner BH, Karanikolas N, Barakat RR, Wong D, **Chi DS**. The Ureteroileocecal Appendicostomy Urinary Reservoir: Comparison of Outcomes In Radiated And Non-Radiated Patients. *J Urol*. 2009;182(5):2376-80.
137. Zivanovic O, Sima CS, Iasonos A, Bell-McGuinn KM, Sabbatini PJ, Leitao MM, Levine DA, Gardner GJ, Barakat RR, **Chi DS**. Exploratory Analysis of Serum CA-125 Response to Surgery and the Risk of Relapse in Patients with FIGO Stage IIIC Ovarian Cancer. *Gynecol Oncol*. 2009;115(2):209-14.
138. Matsuo K, **Chi DS**, Eno ML, Im DD, Rosenshein NB. Vulvar Mucinous Adenocarcinoma Associated with Crohn's Disease: Report of Two Cases. *Gynecol Obstet Invest*. 2009;68(4):276-27.
139. Khoury-Collado F, Glaser GE, Zivanovic O, Sonoda Y, Levine DA, **Chi DS**, Gemignani ML, Barakat RR, Abu-Rustum NR. Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed? *Gynecol Oncol*. 2009;115(3):453-5.
140. Leitao Jr.MM, Natenzon A, Abu-Rustum NR, Brown C, **Chi DS**, Sonoda Y, Levine DA, Gardner G, Barakat RR. Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose barrier (HA-CMC) at the time of laparotomy for ovarian, fallopian tube, or primary peritoneal cancers. *Gynecol Oncol*. 2009 ;115(2):204-8.
141. Abu-Rustum NR, Gomez JD, Alektiar KM, Soslow RA, Hensley ML, Levine DA, Leitao MM Jr., Gardner G, Sonoda Y, **Chi DS**, Barakat RR. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer with negative pelvic lymph nodes. *Gynecol Oncol*. 2009;115(2):236-8.
142. Diaz JP, Tew WP, Zivanovic O, Konner J, Sabbatini PJ, dos Santos LA, Abu-Rustum NR, **Chi DS**, Aghajanian C, Barakat RR. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. *Gynecol Oncol*. 2010;116(3):335-9
143. Zivanovic O, Sima CS, Iasonos A, Hoskins WJ, Pingle PR, Leitao Jr MM, Sonoda Y, Abu-Rustum NR, Barakat RR, **Chi DS**. The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in

- the upper abdomen cephalad to the greater omentum. *Gynecol Oncol.* 2010;116(3):351-7.
144. Shih KK, **Chi DS**, Barakat RR, Leitao Jr MM. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. *Gynecol Oncol.* 2010;116(3):364-9.
 145. Abu-Rustum NR, Zhou Q, Gomez JD, Alektiar KM, Hensley ML, Soslow RA, Levine DA, **Chi DS**, Barakat RR, Iasonos A. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. *Gynecol Oncol.* 2010;116(3):399-403.
 146. Diaz JP, Abu-Rustum NR, Sonoda Y, Downey RJ, Park BJ, Flores RM, Chang K, Leitao MM, Barakat RR, **Chi DS**. Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. *Gynecol Oncol.* 2010;116(3):483-8.
 147. Leitao Jr MM, Kehoe S, Barakat RR, Alektiar K, Rabbitt C, **Chi DS**, Soslow RA, Abu-Rustum NR. Endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma in a background of complex atypical hyperplasia (CAH) and final hysterectomy pathology. *Am J Obstet Gynecol.* 2010;202(3):278.e1-6.
 148. Carter J, **Chi DS**, Brown CL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Levine DA, Baser RE, Raviv L, Barakat RR. Cancer-Related Infertility in Survivorship. *Int J Gynecol Cancer.* 2010;20(1):2-8.
 149. **Chi DS**, Zivanovic O, Barlin JN, Ramirez PT, Teitcher J, Mironov S, Sarasohn D, Iyer R, Dao F, Huh J, Abu-Rustum NR, Sonoda Y, Hricak H, Barakat RR. A Follow-up Study of the Correlation Between Postoperative Computed Tomography (CT) Scan and Primary Surgeon Assessment in Patients with Advanced Ovarian, Tubal, and Peritoneal Carcinoma Reported to Have Undergone Primary Surgical Cytoreduction to Residual Disease ≤ 1 cm. *Int J Gynecol Cancer.* 2010;20(3):353-7.
 150. Tanner EJ, **Chi DS**, Eisenhauer EL, Diaz-Montes TP, Santillan A, Bristow RE. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? *Gynecol Oncol.* 2010;117(2):336-40.
 151. Shih KK, **Chi DS**, Barakat RR, Leitao MM. Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. *Gynecol Oncol.* 2010;117(2):330-5.
 152. Kolev V, Mironov S, Mironov O, Moskowitz C, Ishill N, Gardner GL, Levine DA, Hricak H, Barakat RR, **Chi DS**. The prognostic significance of supra-diaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer. *Int J Gynecol Cancer.* 2010;20(6):979-84.

153. Bristow RE, Palis BE, **Chi DS**, Cliby WA. The National Cancer Data Base Report on Advanced-Stage Epithelial Ovarian Cancer: Impact of Hospital Surgical Case Volume on Overall Survival and Surgical Treatment Paradigm. *Gynecol Oncol.* 2010;118(3):262-7.
154. **Chi DS**, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, Gardner GJ, Leitao M, Levine DA, Sonoda Y, Abu-Rustum NR, Brown CA, Barakat RR. The incidence of major surgical complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. *Gynecol Oncol.* 2010;119(1):38-42.
155. Leitao Jr MM, Han G, Lee LX, Abu-Rustum NR, Brown C, **Chi DS**, Sonoda Y, Levine DA, Gardner GJ, Jewell EE, Barakat RR, Soslow RA. Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk. *Am J Obstet Gynecol.* 2010;203(4):349.
156. Sala E, Kataoka M, Pandit-Taskar N, Ishill N, Mironov S, Moskowitz CS, Mironov O, Collins MA, **Chi DS**, Larson S, Hricak H. Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival. *Radiology.* 2010;257(1):125-34.
157. Leitao Jr MM, Byrum K, Abu-Rustum NR, Brown CL, **Chi DS**, Sonoda Y, Levine DA, Gardner GJ, Barakat RR. Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose barrier (HA-CMC) at the time of laparotomy for uterine or cervical cancers. *Gynecol Oncol.* 2010;119(2):208-211.
158. Shih KK, Zhou Q, Aghajanian C, Huh J, Soslow R, Iasonos A, **Chi DS**, Barakat RR, Abu-Rustum NR. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. *Gynecol Oncol.* 2010;119(2):270-273.
159. Carter J, Sonoda Y, Baser RE, Raviv L, **Chi DS**, Barakat RR, Iasonos A, Brown CL, Abu-Rustum NR. Two-Year Prospective Study Assessing the Emotional, Sexual, and Quality of Life Concerns of Women Undergoing Radical Trachelectomy versus Radical Hysterectomy for Treatment of Early-Stage Cervical Cancer. *Gynecol Oncol.* 2010;119(2):358-365.
160. Sonoda Y, Olvera N, **Chi DS**, Brown CL, Abu-Rustum NR, Levine DA. Pathologic analysis of ex vivo plasma energy tumor destruction in patients with ovarian or peritoneal cancer. *Int J Gynecol Cancer* 2010;20: 1326-1330.
161. Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, **Chi DS**, Bristow RE, Cliby WA. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. *Gynecol Oncol.* 2011;120(1):23-8.

162. Long KC, Levinson KL, Diaz JP, Gardner GJ, **Chi DS**, Barakat RR, Leitao MM Jr. Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancer. *Gynecol Oncol.* 2011;120(1):33-7.
163. Carter J, Raviv L, Sonoda Y, **Chi DS**, Abu-Rustum NR. Recovery issues of fertility-preserving surgery in patients with early-stage cervical cancer and a model for survivorship: the physician checklist. *Int J Gynecol Cancer.* 2011;21(1):106-16.
164. Diaz JP, Gemignani ML, Pandit-Taskar N, Park KJ, Murray MP, **Chi DS**, Sonoda Y, Barakat RR, Abu-Rustum NR. Sentinel lymph node biopsy in the management of early-stage cervical carcinoma. *Gynecol Oncol.* 2011;120 (3):347-352.
165. Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, **Chi DS**, Barakat RR, Abu-Rustum NR. Risk factors for recurrence of ovarian borderline tumors. *Gynecol Oncol.* 2011;120(3):480-4
166. Abu-Rustum NR, Zhou Q, Iasonos A, Alektiar KM, Leitao MM, **Chi DS**, Sonoda Y, Soslow R, Hensley M, Barakat RR. The Revised 2009 FIGO Staging System for Endometrial Cancer: Should the 1988 FIGO Stages IA and IB Be Altered? *Int J Gynecol Cancer* 2011;21: 511-516.
167. Cormier B, Diaz JP, Shih K, Sampson RM, Sonoda Y, Park KJ, Alektiar K, **Chi DS**, Barakat RR, Abu-Rustum NR. Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. *Gynecologic Oncology* 2011;122(2):275-280.
168. Khoury-Collado F, Murray MP, Hensley ML, Sonoda Y, Alektiar KM, Levine DA, Leitao MM, **Chi DS**, Barakat RR, Abu-Rustum NR. Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes. *Gynecol Oncol.* 2011;122(2):251-4.
169. Moxley KM, Fader AN, Rose PG, Case AS, Mutch DG, Berry E, Schink JC, Kim CH, **Chi DS**, Moore KN. Malignant melanoma of the vulva: an extension of cutaneous melanoma? *Gynecol Oncol.* 2011;122(3):612-7.
170. Shih KK, Yun E, Gardner GJ, Barakat RR, **Chi DS**, Leitao Jr MM. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. *Gynecol Oncol.* 2011;122(3):608-11.
171. Zang RY, Harter P, **Chi DS**, Sehouli J, Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. *Br J Cancer.* 2011;105(7):890-6.

172. Smyth EC, Flavin M, Pulitzer MP, Gardner GJ, Costantino PD, **Chi DS**, Bogatch K, Chapman PB, Wolchok JD, Schwartz GK, Carvajal RD. Treatment of locally recurrent mucosal melanoma with topical imiquimod. *J Clin Oncol*. 2011;29(33):e809-11.
173. Shih KK, Garg K, Soslow RA, **Chi DS**, Abu-Rustum NR, Barakat RR. Accuracy of frozen section diagnosis of ovarian borderline tumor. *Gynecol Oncol*. 2011 ;123(3):517-21.
174. Tanner EJ, Leitaio MM Jr, Garg K, **Chi DS**, Sonoda Y, Gardner GJ, Barakat RR, Jewell E. The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. *Gynecol Oncol*. 2011;123(3):548-52.
175. Mironov O, Sala E, Mironov S, Pannu H, **Chi DS**, Hricak H. Thoracic metastases in advanced ovarian cancer: comparison between computed tomography and video assisted thoracic surgery. *J Gynecol Oncol* 2011;22(4):260-268.
176. Mironov O, Ishill NM, Mironov S, Vargas HA, Zheng J, Moskowitz CS, Sonoda Y, Papas R, **Chi DS**, Hricak H. Pleural Effusion Detected by Preoperative CT Prior to Primary Cytoreduction for Stage III and IV Ovarian Carcinoma: Impact on Survival. *Radiology*. 2011;258(3):776-84
177. **Chi DS**, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitaio MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR. An Analysis of Patients with Bulky Advanced Stage Ovarian, Tubal, and Peritoneal Carcinoma Treated with Primary Debulking Surgery (PDS) During an Identical Time Period as the Randomized EORTC-NCIC Trial of PDS vs Neoadjuvant Chemotherapy (NACT). *Gynecol Oncol*. 2012;124(1):10-4.
178. Khoury-Collado F, Einstein HM, Bochner BH, Alektiar KM, Sonoda Y, Abu-Rustum NR, Brown CL Gardner GJ, Barakat RR, **Chi DS**. Pelvic exenteration with curative intent for recurrent uterine malignancies. *Gynecol Oncol*. 2012;124(1):42-7.
179. Tian WJ, **Chi DS**, Sehouli J, Trope' CG, Jiang R, Ayhan A, Cormio G, XingY, Breitbach GP, Braicu EI, Rabbitt CA, Oksefjell H, Fotopoulou C, Meerpohl HG, du Bois A, Berek JS, Zang RY, Harter P. A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection. *Ann Surg Oncol*. 2012;19(2):597-604.
180. Zivanovic O, Jacks LM, Iasonos A, Leitaio MM, Soslow RA, Veras E, **Chi DS**, Barakat RR, Brennan MF, Hensley ML. Development of a nomogram to provide individualized prediction of 5-year overall survival for patients diagnosed with uterine leiomyosarcoma. *Cancer*. 2012;118(3):660-669.
181. Long KC, Zhou Q, Hensley M, Alektiar K, Gomez J, Gardner GJ, **Chi DS**, Barakat RR, Nadeem R. Abu-Rustum. Patterns of recurrence of 1988 FIGO stage IC endometrioid endometrial cancer. *Gynecol Oncol*. 2012;125(1):99-102.

182. Barlin JN, Yu C, Hill EK, Zivanovic O, Kolev V, Levine DA, Sonod Y, Abu-Rustum NR, Huh J, Barakat RR, Kattan MW, **Chi DS**. Nomogram for predicting five-year survival after primary surgery for epithelial ovarian cancer. *Gynecol Oncol*. 2012;125(1):25-30.
183. Leitao MM Jr, Briscoe G, Santos K, Windner A, Jewell E, **Chi DS**, Abu-Rustum NR, Sonoda Y, Brown C, Levine DA, Barakat RR, Gardner GJ. Introduction of a computer-based surgical platform in the surgical care of patients with newly diagnosed uterine cancer: outcomes and impact on approach. *Gynecologic Oncology*. 2012;125(2):394-399.
184. Andikyan V, Khoury-Collado F, Sonoda Y, Gerst SR, Alektiar KM, Sandhu JS, Bochner BH, Barakat RR, Boland PJ, **Chi DS**. Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: an update on out of the box surgery. *Gynecologic Oncology*. 2012;125 (2):404-408.
185. Leitao MM, Zivanovic O, **Chi DS**, Hensley ML, O’Cearbhaill R, Soslow RA, Barakat RR. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. *Gynecologic Oncology*. 2012;125 (2):409-413.
186. LakhmanY, Akin O, Sohn MJ, Zheng J, Moskowitz CS, Iyer RB, Barakat RR, Sabbatini PJ, **Chi DS**, Hricak H. Early Post-operative CT as a Prognostic Biomarker in Patients with Advanced Ovarian, Tubal, and Primary Peritoneal Cancer Deemed Optimally Debulked at Primary Cytoreductive Surgery. *AJR Am J Roentgenol*. 2012;198(6):1453-9.
187. Barlin JN, Dao F, Zgheib NB, Ferguson SE, Sabbatini PJ, Hensley ML, Bell-McGuinn KM, Konner J, Tew WP, Aghajanian C, **Chi DS**. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. *Gynecol Oncol*. 2012;125(3):621-4.
188. Kim CH, Abu-Rustum NR, **Chi DS**, Gardner GJ, Leitao MM Jr, Carter J, Barakat RR, Sonoda Y. Reproductive outcomes of patients undergoing radical trachelectomy for early-stage cervical cancer. *Gynecol Oncol*. 2012;125(3):585-8.
189. Barlin JN, Khoury-Collado F, Kim CH, Leitao MM Jr, **Chi DS**, Sonoda Y, Alektiar K, DeLair DF, Barakat RR, Abu-Rustum NR. The Importance of Applying a Sentinel Lymph Node Mapping Algorithm in Endometrial Cancer Staging: Beyond Removal of Blue Nodes. *Gynecol Oncol*. 2012;125(3):531-5.
190. Tanner EJ, Long K, Zhou Q, Brightwell R, Gardner GJ, Abu-Rustum NR, Leitao MM Jr, Sonoda Y, Barakat RR, Iasonos A, **Chi DS**. Impact of Operative Start Time on Surgical Outcomes in Patients Undergoing Primary Cytoreduction for Advanced Ovarian Cancer *Gynecol Oncol*. 2012;126(1):58-63.

191. Lowery M, Klimstra D, Hedvat C, Jarnagin W, **Chi D**, O'Reilly EM. A case of synchronous pancreatic ductal adenocarcinoma and ovarian mucinous cystic neoplasm: use of kras mutation molecular phenotyping to demonstrate independent primary origin. *Gastrointest Cancer Res.* 2012;5(2):67-70.
192. DiMaio CJ, Dorfman MP, Gardner GJ, Nash GM, Schattner MA, Markowitz AJ, **Chi DS**, Gerdes H. The use of covered esophageal self-expanding metal stents (cSEMS) for the management of post-operative colo-rectal anastomotic leaks. *Gastrointest Endosc.* 2012;76(2):431-5.
193. Andikyan V, Khoury-Collado F, Gerst SR, Talukdar S, Bochner BH, Sandhu J, Abu-Rustum NR, Sonoda Y, Barakat RR, **Chi DS**. Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: review of surgical technique, complications, and outcome. *Gynecol Oncol.* 2012;126(3):346-50.
194. Andikyan V, Rezk Y, Einstein MH, Gualtiere G, Leitao MM Jr, Sonoda Y, Abu-Rustum NR, Barakat RR, Basch EM, **Chi DS**. A Prospective Study of the Feasibility and Acceptability of a Web-Based, Electronic Patient-Reported Outcomes System in Assessing Patient Recovery after Major Gynecologic Cancer Surgery. *Gynecol Oncol.* 2012;127(2):273-7.
195. Wethington SL, Cibula D, Duska LR, Garrett L, Kim CH, **Chi DS**, Sonoda Y, Abu-Rustum NR. An International Series on Abdominal Trachelectomy: 101 patients and 28 pregnancies. *Int J Gynecol Cancer.* 2012;22(7):1251-7.
196. Barlin JN, Wysham WZ, Ferda AM, Khoury-Collado F, Cassella DK, Alektiar KM, Hensley ML, **Chi DS**, Barakat RR, Abu-Rustum NR. Location of Disease in Patients Who Die From Endometrial Cancer: A Study of 414 Patients From a Single Institution. *Int J Gynecol Cancer.* 2012;22(9):1527-31.
197. Tanner EJ, Long KC, Feffer JB, Leitao MM Jr, Abu-Rustum NR, Barakat RR, **Chi DS**, Gardner GJ. Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer. *Gynecol Oncol.* 2013;128(1):83-87.
198. Rezk YA, Hurley KE, Carter J, Dao F, Bochner BH, Aubey JJ, Caceres A, Einstein MH, Abu-Rustum NR, Barakat RR, **Chi DS**. A Prospective Study of Quality of Life in Patients Undergoing Pelvic Exenteration: Interim Results. *Gynecol Oncol.* 2013;128:191-197.
199. Lakhi N, Serur E, **Chi DS**. Management of intravascular leiomyomatosis. *Am J Obstet Gynecol.* 2013;208(4):333.
200. Sandadi S, Tanner E, Khoury-Collado F, Kostolias A, Makker V, **Chi DS**, Sonoda Y, Barakat R, Abu-Rustum NR. Radical surgery with individualized post-operative

radiation for stage IB cervical cancer: oncologic outcomes and severe complications. *International Journal of Gynecological Cancer*; 2013;23(3):553 - 558.

201. Barlin JN, Long KC, Tanner EJ, Gardner GJ, Leitao MM, Levine DA, Sonoda Y, Abu-Rustum NR, Barakat RR, **Chi DS**. Optimal (≤ 1 cm) but Visible Residual Disease: Is Extensive Debulking Warranted? *Gynecol Oncol.*;2013;130:284-288.
202. Andikyan V, Khoury-Collado F, Sandadi S, Tew WP, O'Cearbhaill RE, Konner JA, Sonoda Y, Barakat RR, **Chi DS**, Abu-Rustum NR. Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies. *Int J Gynecol Cancer*. 2013;23(5):923-8.
203. Wethington, SL, Sonoda Y, Park KJ, Alektiar KM, Tew WP, **Chi DS**, Leitao MM, Jewell EL, Barakat RR, Abu-Rustum NR. Expanding the indications for radical trachelectomy a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters. *International Journal of Gynecological Cancer* 2013;23(6):1092-1098 .
204. Barlin JN, Jelinic P, Olvera J, Bogomolny F, Bisogna M, Dao F, Barakat RR, **Chi DS**, Levine DA. Validated Gene Targets Associated with Curatively Treated Advanced Serous Ovarian Carcinoma. *Gynecol Oncol*. 2013;128(3):512-7.
205. Burger IA, Vargas HA, Donati OF, Andikyan V, Sala E, Gonen M, Goldman D, **Chi DS**, Schoder H, Hricak H. The value of ^{18}F -FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. *Gynecol Oncol*. 2013;129(3):586-92.
206. Donati OF, Lakhman Y, Sala E, Burger IA, Vargas HA, Goldman DA, Andikyan V, Park KJ, **Chi DS**, Hricak H. Role of preoperative MR imaging in the evaluation of patients with treatment-resistant or recurrent gynecologic malignancies prior to pelvic exenteration. *Eur Radiol*. 2013;23(10):2906-15.
207. Gupta N, Rodriguez E, Andikyav V, Salob SP. MD, **Chi DS**. A case of carcinoma in situ of the vulva treated with sinecatechins with complete response. *Gynecol Oncol Case Rep*. 2013; 6:10-12.
208. Vargas HA, Burger IA, Donati OF, Andikyan V, Lakhman Y, Goldman DA, Schroder H, **Chi DS**, Sala E, Hricak H. Magnetic Resonance Imaging/Positron Emission Tomography Provides a Roadmap for Surgical Planning and Serves as a Predictive Biomarker in Patients With Recurrent Gynecological Cancers Undergoing Pelvic Exenteration. *Int J Gynecol Cancer*. 2013;23(8):1512-9.
209. Long KC, Tanner EJ, Frey M, Leitao MM, Levine DA, Gardner GJ, Sonoda Y, Abu-Rustum NR, Barakat RR, **Chi DS**. Intraoperative hypothermia during primary surgical cytoreduction for advanced ovarian cancer: risk factors and associations with postoperative morbidity. *Gynecol Oncol*. 2013;131(3):525-30.
210. Andikyan A, Khoury-Collado F, Sandadi S, Park KJ, Hussein YR, Brown CL, Sonoda Y, **Chi DS**, Barakat RR, Abu-Rustum NR. Cervical conization and sentinel lymph node

mapping in the treatment of stage I cervical cancer: is less enough? *Int J Gynecol Cancer*. 2014;24(1):113-7.

211. Sandadi S, Gadzinski J, Lee S, **Chi DS**, Jewell E, Brown C, Gardner G, Sonoda Y, Barakat RR, Leitao Jr MM. Fellowship learning curve associated with completing a robotic assisted total laparoscopic hysterectomy. *Gynecol Oncol*. 2014;132(1):102-6
213. Sandadi S, Long K, Andikyan V, Vernon J, Zivanovic O, Eisenhauer EL, Levine DA, Sonoda Y, Barakat RR, **Chi DS**. Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. *Gynecol Oncol*. 2014 ;132(2):299-302.
214. Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, **Chi DS**. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. *Gynecol Oncol*. 2014 Sep;134(3):455-61.
215. Suidan RS, St Clair CM, Lee SJ, Barlin JN, Long Roche KC, Tanner EJ, Sonoda Y, Barakat RR, Zivanovic O, **Chi DS**. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer. *Gynecol Oncol*. 2014 Sep;134(3):468-72.
216. Suidan RS, Zhou Q, Iasonos A, O'Cearbhaill RE, **Chi DS**, Long Roche KC, Tanner EJ, Denesopolis J, Barakat RR, Zivanovic O. Prognostic Significance of the Number of Postoperative Intraperitoneal Chemotherapy Cycles for Patients With Advanced Epithelial Ovarian Cancer. *Int J Gynecol Cancer*. 2015;25(4):599-606
217. Suidan RS, Leitao MM Jr, Zivanovic O, Gardner GJ, Long Roche KC, Sonoda Y, Levine DA, Jewell EL, Brown CL, Abu-Rustum NR, Charlson ME, **Chi DS**. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. *Gynecol Oncol*. 2015 Aug;138(2):246-51
218. Mantha S, Sarasohn D, Ma W, Devlin SM, **Chi DS**, Roche KL, Suidan RS, Woo K, Soff GA. Ovarian vein thrombosis after debulking surgery for ovarian cancer: epidemiology and clinical significance. *Am J Obstet Gynecol*. 2015 Aug;213(2):208
219. Burger IA, Goldman DA, Vargas HA, Kattan MW, Yu C, Kou L, Andikyan V, **Chi DS**, Hricak H, Sala E. Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer. *Gynecol Oncol*. 2015 Sep;138(3):554-9
220. Vargas HA, Burger IA, Goldman DA, Miccò M, Sosa RE, Weber W, **Chi DS**, Hricak H, Sala E. Volume-based quantitative FDG PET/CT metrics and their association with

optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. *Eur Radiol.* 2015 Nov;25(11):3348-53. doi: 10.1007/s00330-015-3729-9.

PMID:25916387

221. Davenport SM, Suidan RS, Huang J, Hyman DM, **Chi DS**. Primary debulking surgery for metastatic cervical adenocarcinoma: A case report. *Gynecol Oncol Rep.* 2015 Oct 27;14:23-5. doi: 10.1016/j.gore.2015.09.004.
PMID:26793767
222. Lakhman Y, D'Anastasi M, Miccò M, Scelzo C, Vargas HA, Nougaret S, Sosa RE, **Chi DS**, Abu-Rustum NR, Hricak H, Sala E. Second-Opinion Interpretations of Gynecologic Oncologic MRI Examinations by Sub-Specialized Radiologists Influence Patient Care. *Eur Radiol.* 2016 Jul;26(7):2089-98. doi: 10.1007/s00330-015-4040-5.
PMID:26494640
223. Leitaio MM, Narain WR, Boccamazzo D, Sioulas V, Cassella D, Ducie JA, Eriksson AG, Sonoda Y, **Chi DS**, Brown CL, Levine DA, Jewell EL, Zivanovic O, Barakat RR, Abu-Rustum NR, Gardner GJ. Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer. *Ann Surg Oncol.* 2016 Jul;23(7):2192-8. doi: 10.1245/s10434-015-5062-6.
PMID:26744108
224. Schiavone MB, Bielen MS, Gardner GJ, Zivanovic O, Jewell EL, Sonoda Y, Barakat RR, **Chi DS**, Abu-Rustum NR, Leitaio MM Jr. Herniation formation in women undergoing robotically assisted laparoscopy or laparotomy for endometrial cancer. *Gynecol Oncol.* 2016 Mar;140(3):383-6. doi: 10.1016/j.ygyno.2016.01.010. Epub 2016 Jan 8.
PMID:26777989
225. Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, Eriksson AG, Gardner GJ, Sonoda Y, Levine DA, Aghajanian C, **Chi DS**, Abu-Rustum NR, Zivanovic O. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. *Gynecol Oncol.* 2016 Mar;140(3):436-42. doi: 10.1016/j.ygyno.2016.01.008. Epub 2016 Jan 9.
PMID:26777991
226. Cowan RA, Black DR, Hoang LN, Park KJ, Soslow RA, Backes FJ, Gardner GJ, Abu-Rustum NR, Leitaio MM Jr, Eisenhauer EL, **Chi DS**. A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's disease. *Gynecol Oncol.* 2016 Jul;142(1):139-43. doi: 10.1016/j.ygyno.2016.04.028.
PMID:27112632
227. Schlappé BA, Mueller JJ, Zivanovic O, Gardner GJ, Roche KL, Sonoda Y, **Chi DS**, O'Cearbhaill RE. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high

- intraperitoneal chemotherapy utilization center. *Gynecol Oncol*. 2016 Jul;142(1):13-8. doi: 10.1016/j.ygyno.2016.05.015.
PMID:27189456
228. Tseng JH, Suidan RS, Zivanovic O, Gardner GJ, Sonoda Y, Levine DA, Abu-Rustum NR, Tew WP, **Chi DS**, Long Roche K. Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. *Gynecol Oncol*. 2016 Aug;142(2):217-24. doi: 10.1016/j.ygyno.2016.05.035.
PMID:27261325
229. Cowan RA, Suidan RS, Andikyan V, Rezk YA, Einstein MH, Chang K, Carter J, Zivanovic O, Jewell EJ, Abu-Rustum NR, Basch E, **Chi DS**. Electronic patient-reported outcomes from home in patients recovering from major gynecologic cancer surgery: A prospective study measuring symptoms and health-related quality of life. *Gynecol Oncol*. 2016 Nov;143(2):362-366. doi: 10.1016/j.ygyno.2016.08.335.
PMID:27637366
230. Mueller JJ, Kelly A, Zhou Q, Iasonos A, Long Roche K, Sonoda Y, O'Cearbhaill RE, Zivanovic O, **Chi DS**, Gardner GJ. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. *Gynecol Oncol*. 2016 Dec;143(3):496-503. doi:10.1016/j.ygyno.2016.09.014.
PMID:27692668
231. Margolis B, Kim SW, **Chi DS**. Long-term survival after anterior pelvic exenteration and total vaginectomy for recurrent endometrial carcinoma with metastatic inguinal nodes at the time of surgery. *Gynecol Oncol Rep*. 2016 Dec 29;19:39-41. doi:10.1016/j.gore.2016.12.007. eCollection 2017 Feb.
PMID: 28070552
232. Tanner EJ, Dun E, Sonoda Y, Olawaiye AB, **Chi DS**. A Comparison of Thermal Plasma Energy Versus Argon Beam Coagulator-Induced Intestinal Injury After Vaporization in a Porcine Model. *Int J Gynecol Cancer*. 2017 Jan;27(1):177-182. doi:10.1097/IGC.0000000000000849.
PMID:27922979
233. Cowan RA, Eriksson AG, Jaber SM, Zhou Q, Iasonos A, Zivanovic O, Leitao MM Jr, Abu-Rustum NR, **Chi DS**, Gardner GJ. A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. *Gynecol Oncol*. 2017 May;145(2):230-235. doi: 10.1016/j.ygyno.2017.02.010.
PMID: 28285846
234. Sinno AK, Li X, Thompson RE, Tanner EJ 3rd, Levinson KL, Stone RL, Temkin SM, Fader AN, **Chi DS**, Long Roche K. Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care.

Gynecol Oncol. 2017 Jun;145(3):493-499. doi: 10.1016/j.ygyno.2017.03.020
PMID:28366546

235. Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H,. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. *Gynecol Oncol.* 2017 Apr;145(1):27-31. doi: 10.1016/j.ygyno.2017.02.020. PMID:28209497
236. Sioulas VD, Schiavone MB, Kadouri D, Zivanovic O, Roche KL, O'Cearbhaill R, Abu-Rustum NR, Levine DA, Sonoda Y, Gardner GJ, Leitao MM Jr, **Chi DS**. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? *Gynecol Oncol.* 2017 Apr;145(1):15-20. doi: 10.1016/j.ygyno.2017.02.023. PMID:28238354
237. Ganesh K, Shah RH, Vakiani E, Nash GM, Skottowe HP, Yaeger R, Cercek A, Lincoln A, Tran C, Segal NH, Reidy DL, Varghese A, Epstein AS, Sonoda Y, **Chi D**, Guillem J, Temple L, Paty P, Hechtman J, Shia J, Weiser M, Aguilar JG, Kemeny N, Berger MF, Saltz L, Stadler ZK. Clinical and genetic determinants of ovarian metastases from colorectal cancer. *Cancer.* 2017 Apr 1;123(7):1134-1143. doi: 10.1002/cncr.30424. PMID: 27875625
238. Aloisi A, Pesce JE, Paraghamian SE, **Chi DS**, Rieth EF. Bilateral Otorrhagia after Robotically Assisted Gynecologic Surgery in the Setting of a Reduced Trendelenburg Position and Low-Pressure Pneumoperitoneum: A Case Report and Review of the Literature. *J Minim Invasive Gynecol.* 2017 Apr 28. pii: S1553-4650(17)30265-0. doi: 10.1016/j.jmig.2017.04.009. PMID: 28461176
239. Wu ES, Aguinaldo ET, Hussein YR, Suidan RS, **Chi DS**. Benign metastasizing leiomyomas thought to be nodal metastases in a case of ovarian cancer. *Taiwan J Obstet Gynecol.* 2017 Aug;56(4):564-565. PMID: 28805621.
240. Eriksson AGZ, Graul A, Yu MC, Halko A, **Chi DS**, Zivanovic O, Gardner GJ, Sonoda Y, Barakat RR, Abu-Rustum NR, Leitao MM Jr. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. *Gynecol Oncol.* 2017 Aug;146(2):263-267. PMID: 28527673.
241. Cowan RA, Tseng J, Murthy V, Srivastava R, Long Roche KC, Zivanovic O, Gardner GJ, **Chi DS**, Park BJ, Sonoda Y. Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer. *Gynecol Oncol.* 2017 Nov;147(2):262-266. PMID: 28888540.

242. Schiavone MB, Moukarzel L, Leong K, Zhou QC, Afonso AM, Iasonos A, Roche KL, Leitao MM Jr, **Chi DS**, Abu-Rustum NR, Zivanovic O. Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery. *Gynecol Oncol*. 2017 Oct;147(1):115-119. PMID: 28734498; PMC5605426.
243. Oseledchyk A, Leitao MM Jr, Konner J, O'Cearbhaill RE, Zamarin D, Sonoda Y, Gardner GJ, Long Roche K, Aghajanian CA, Grisham RN, Brown CL, Snyder A, **Chi DS**, Soslow RA, Abu-Rustum NR, Zivanovic O. Adjuvant Chemotherapy in Patients with Stage I Endometrioid or Clear Cell Ovarian Cancer in the Platinum Era: A Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013. *Ann Oncol*. 2017 Dec 1;28(12):2985-2993. PMID:29667339
244. Cowan RA, Tseng J, Ali N, Dearie H, Murthy V, Gennarelli RL, Iasonos A, Abu-Rustum NR, **Chi DS**, Long Roche KC, Brown CL. Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center. *Gynecol Oncol*. 2018 Apr;149(1):43-48. doi: 10.1016/j.ygyno.2017.11.012. PMID: 29605049
245. Tseng JH, Cowan RA, Zhou Q, Iasonos A, Byrne M, Polcino T, Polen-De C, Gardner GJ, Sonoda Y, Zivanovic O, Abu-Rustum NR, Long Roche K, **Chi DS**. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival? *Gynecol Oncol*. 2018 Oct;151(1):24-31. doi: 10.1016/j.ygyno.2018.08.014. Epub 2018 Aug 17. PMID: 30126704
246. Tseng JH, Cowan RA, Afonso AM, Zhou Q, Iasonos A, Ali N, Thompson E, Sonoda Y, O'Cearbhaill RE, **Chi DS**, Abu-Rustum NR, Long Roche K. Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer. *Gynecol Oncol*. 2018 Nov;151(2):287-293. doi: 10.1016/j.ygyno.2018.08.024. Epub 2018 Sep 2. PMID:30185381
247. Tanner EJ, Filippova OT, Gardner GJ, Long Roche KC, Sonoda Y, Zivanovic O, Fischer M, **Chi DS**. A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. *Gynecol Oncol*. 2018 Dec;151(3):433-437. doi: 10.1016/j.ygyno.2018.10.006. Epub 2018 Oct 16. PMID: 30336947
248. Filippova OT, **Chi DS**, Long Roche K, Sonoda Y, Zivanovic O, Gardner GJ, Tew WP, O'Cearbhaill R, Sarraf S, Sun SW, Alexander K, Korc-Grodzicki B, Shahrokni A. Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. *Gynecol Oncol*. 2019 Jul;154(1):77-82. doi: 10.1016/j.ygyno.2019.04.683. Epub 2019 May 8. PMID: 31078241
249. Stasencko M, Cybulska P, Feit N, Makker V, Konner J, O'Cearbhaill RE, Alektiar KM, Beal K, Gardner GJ, Long Roche KC, Sonoda Y, **Chi DS**, Zivanovic O, Leitao MM Jr,

- Cadoo KA, Tew WP. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. *Gynecol Oncol*. 2019 Jul;154(1):144-149. doi: 10.1016/j.ygyno.2019.05.004. Epub 2019 May 18. PMID: 31113680
250. Cybulska P, Sioulas V, Orfanelli T, Zivanovic O, Mueller JJ, Broach VA, Long Roche KC, Sonoda Y, Hensley ML, O'Cearbhaill RE, **Chi DS**, Alektiar KM, Abu-Rustum NR, Leita MM Jr. Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. *Gynecol Oncol*. 2019 Aug;154(2):333-337. doi: 10.1016/j.ygyno.2019.05.015. Epub 2019 Jun 12. PMID: 31200927
 251. Cowan RA, Shuk E, Byrne M, Abu-Rustum NR, **Chi DS**, Boutin-Foster C, Brown CL, Long Roche K. Factors Associated With Use of a High-Volume Cancer Center by Black Women With Ovarian Cancer. *J Oncol Pract*. 2019 Sep;15(9):e769-e776. doi: 10.1200/JOP.18.00741. Epub 2019 Jul 23. PMID: 31335249
 252. Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, Guyon F, Gregg S, Mosgaard BJ, Reinthaller A, Hilpert F, Schade-Brittinger C, **Chi DS**, Mahner S. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). *Int J Gynecol Cancer*. 2019 Oct;29(8):1327-1331. doi: 10.1136/ijgc-2019-000682. Epub 2019 Aug 15. PMID: 31420412
 253. Himoto Y, Cybulska P, Shitano F, Sala E, Zheng J, Capanu M, Nougaret S, Nikolovski I, Vargas HA, Wang W, Mueller JJ, **Chi DS**, Lakhman Y. Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer? *Gynecol Oncol*. 2019 Nov;155(2):192-200. doi: 10.1016/j.ygyno.2019.08.011. Epub 2019 Sep 12. PMID: 31521322
 254. Cybulska P, Hayes SA, Spirtos A, Rafizadeh MJ, Filippova OT, Leita M, Zivanovic O, Sonoda Y, Mueller J, Lakhman Y, Long K, **Chi DS**. Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer. *Int J Gynecol Cancer*. 2019 Nov;29(9):1377-1380. doi: 10.1136/ijgc-2019-000829. Epub 2019 Oct 1. PMID: 31575614
 255. Pourmaleki M, Young JH, Socci ND, Chiang S, Edelweiss M, Li Y, Zhang M, Roshal L, **Chi DS**, Busam KJ, Mellinshoff IK, Hollmann TJ. Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A. *Oncotarget*. 2019 Oct 22;10(58):6152-6167. doi: 10.18632/oncotarget.27247. eCollection 2019 Oct 22. PMID: 31692889
 256. Leita MM Jr, Zhou QC, Gomez-Hidalgo NR, Iasonos A, Baser R, Mezzancello M, Chang K, Ward J, **Chi DS**, Long Roche K, Sonoda Y, Brown CL, Mueller JJ, Gardner GJ, Jewell EL, Broach V, Zivanovic O, Dowdy SC, Mariani A, Abu-Rustum NR. Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy.

Gynecol Oncol. 2020 Jan;156(1):147-153. doi: 10.1016/j.ygyno.2019.11.003. Epub 2019 Nov 25. PMID: 31780238

257. Liu YL, Filippova OT, Zhou Q, Iasonos A, **Chi DS**, Zivanovic O, Sonoda Y, Gardner GJ, Broach VA, O'Cearbhaill RE, Konner JA, Aghajanian C, Long Roche K, Tew WP. Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. J Gynecol Oncol. 2020 Jan;31(1):e17. doi: 10.3802/jgo.2020.31.e17. PMID: 31833259
258. Brandt B, Sioulas V, Basaran D, Kuhn T, LaVigne K, Gardner GJ, Sonoda Y, **Chi DS**, Long Roche KC, Mueller JJ, Jewell EL, Broach VA, Zivanovic O, Abu-Rustum NR, Leitao MM Jr. Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31868-2. doi: 10.1016/j.ygyno.2019.12.038. [Epub ahead of print] PMID: 31918996
259. Weigelt B, Vargas HA, Selenica P, Geyer FC, Mazaheri Y, Blecula P, Conlon N, Hoang LN, Jungbluth AA, Snyder A, Ng CKY, Papanastasiou AD, Sosa RE, Soslow RA, **Chi DS**, Gardner GJ, Shen R, Reis-Filho JS, Sala E. Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer. JCO Precis Oncol. 2019 Jun 6;3:PO.18.00410. doi: 10.1200/PO.18.00410. eCollection 2019. PMID: 32914032
260. Cadoo KA, Mandelker DL, Mukherjee S, Stewart C, DeLair D, Ravichandran V, Srinivasan P, Hurley D, Kemel Y, Arnold AG, Sheehan M, Pradhan N, Joseph V, **Chi DS**, Gardner GJ, Jewell EL, Leitao MM Jr, Roche KL, Mueller JJ, Sonoda Y, Zivanovic O, Walsh M, Carlo MI, Berger MF, Hyman D, Zhang L, Robson ME, Offit K, Aghajanian C, Rustum NRA, Stadler Z. Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer. JCO Precis Oncol. 2019;3:PO.18.00338. doi: 10.1200/po.18.00338. Epub 2019 Apr 25. PMID: 32775946
261. Broach V, Abu-Rustum NR, Sonoda Y, Brown CL, Jewell E, Gardner G, **Chi DS**, Zivanovic O, Leitao MM Jr. Evolution and outcomes of sentinel lymph node mapping in vulvar cancer. Int J Gynecol Cancer. 2020 Mar;30(3):383-386. doi: 10.1136/ijgc-2019-000936. Epub 2020 Feb 18. PMID: 32075896
262. Lugo Santiago N, Smith E, Cox M, Wan CS, Tchabo NE, Awowole I, Broach V, **Chi DS**. Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation. Obstet Gynecol. 2020 Jun;135(6):1270-1274. doi: 10.1097/AOG.0000000000003864. PMID: 32459417
263. Pedra Nobre S, Mueller JJ, Gardner GJ, Long Roche K, Brown CL, Soslow RA, Alektiar KM, Sonoda Y, Broach VA, Jewell EL, Zivanovic O, **Chi DS**, Abu-Rustum NR, Leitao MM Jr. Comparison of minimally invasive versus open surgery in the treatment of

- endometrial carcinosarcoma. *Int J Gynecol Cancer*. 2020 Aug;30(8):1162-1168. doi: 10.1136/ijgc-2020-001573. Epub 2020 Jul 20.PMID: 32690592
264. Filippova OT, Kim SW, Cowan RA, Chi AJ, Iasonos A, Zhou QC, Broach V, Zivanovic O, Long Roche K, Sonoda Y, Gardner G, **Chi DS**. Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism. *Int J Gynecol Cancer*. 2020 Aug;30(8):1183-1188. doi: 10.1136/ijgc-2020-001368. Epub 2020 Jul 13.PMID: 32665236
 265. Moukarzel LA, Byrne ME, Leiva S, Wu M, Zhou QC, Iasonos A, Abu-Rustum NR, Sonoda Y, Gardner G, Leitao MM Jr, Broach VA, **Chi DS**, Long Roche K, Zivanovic O. The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. *Gynecol Oncol*. 2020 Aug;158(2):397-401. doi: 10.1016/j.ygyno.2020.05.022. Epub 2020 May 24.PMID: 32460995
 266. Liu YL, Zhou QC, Iasonos A, Filippova OT, **Chi DS**, Zivanovic O, Sonoda Y, Gardner G, Broach V, OCearbhaill R, Konner JA, Aghajanian CA, Long K, Tew W. Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. *Int J Gynecol Cancer*. 2020 Oct;30(10):1554-1561. doi: 10.1136/ijgc-2019-000989. Epub 2020 Jun 9.PMID: 32522770
 267. Zivanovic O, Chen LY, Vickers A, Straubhar A, Baser R, Veith M, Aiken N, Carter J, Curran K, Simon B, Mueller J, Jewell E, **Chi DS**, Sonoda Y, Abu-Rustum NR, Leitao MM Jr. Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study. *Gynecol Oncol*. 2020 Oct;159(1):187-194. doi: 10.1016/j.ygyno.2020.07.004. Epub 2020 Jul 24.PMID: 32718730
 268. Aloisi A, Tseng J, Kuhn T, Feinberg J, **Chi DS**, Brown CL, Mueller JJ, Gardner GJ, Zivanovic O, Jewell EL, Long Roche K, Broach V, Abu-Rustum NR, Leitao MM Jr. Robotic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. *Ann Surg Oncol*. 2020 Oct;27(10):3772-3780. doi: 10.1245/s10434-020-08475-w. Epub 2020 Apr 23.PMID: 32328983
 269. Stasencko M, Jayakumaran G, Cowan R, Broach V, **Chi DS**, Rossi A, Hollman TJ, Zehir A, Abu-Rustum NR, Leitao MM Jr. Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget's Disease of the Vulva. *JCO Precis Oncol*. 2020 Sep 15;4:PO.20.00073. doi: 10.1200/PO.20.00073. eCollection 2020.PMID: 33015527
 270. Jiménez-Sánchez A, Cybulska P, Mager KL, Koplev S, Cast O, Couturier DL, Memon D, Selenica P, Nikolovski I, Mazaheri Y, Bykov Y, Geyer FC, Macintyre G, Gavarró LM, Drews RM, Gill MB, Papanastasiou AD, Sosa RE, Soslow RA, Walther T, Shen R, **Chi DS**, Park KJ, Hollmann T, Reis-Filho JS, Markowitz F, Beltrao P, Vargas HA, Zamarin D, Brenton JD, Snyder A, Weigelt B, Sala E, Miller ML. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.

Nat Genet. 2020 Jun;52(6):582-593. doi: 10.1038/s41588-020-0630-5. Epub 2020 Jun 1.PMID: 32483290

271. Straubhar AM, Filippova OT, Cowan RA, Lakhman Y, Sarasohn DM, Nikolovski I, Torrisi JM, Ma W, Abu-Rustum NR, Gardner GJ, Sonoda Y, Zivanovic O, **Chi DS**, Long Roche K. A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. *Gynecol Oncol*. 2020 Sep;158(3):608-613. doi: 10.1016/j.ygyno.2020.05.041. Epub 2020 Jun 6.PMID: 32518012
272. Boerner T, Filippova OT, Chi AJ, Iasonos A, Zhou QC, Long Roche K, Zivanovic O, Park BJ, Huang J, Jones DR, Abu-Rustum NR, Gardner G, Sonoda Y, **Chi DS**. Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. *Gynecol Oncol*. 2020 Oct;159(1):66-71. doi: 10.1016/j.ygyno.2020.07.101. Epub 2020 Aug 10.PMID: 32792282
273. Plett H, Filippova OT, Garbi A, Kommoss S, Rosendahl M, Langstraat C, Phadnis S, Muallem MZ, Baert T, **Chi DS**, Aletti GD, Taran FA, Ramspott JP, Zivanovic O, du Bois A, Sonoda Y, Gardner G, Traut A, Roche KL, Harter P. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. *Gynecol Oncol*. 2020 Nov;159(2):434-441. doi: 10.1016/j.ygyno.2020.08.028. Epub 2020 Sep 9.PMID: 32919778
274. Liu YL, Zhou QC, Iasonos A, **Chi DS**, Zivanovic O, Sonoda Y, Gardner G, Broach V, O'Cearbhaill R, Konner JA, Grisham R, Aghajanian CA, Abu-Rustum NR, Tew W, Long Roche K. Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. *Int J Gynecol Cancer*. 2020 Dec;30(12):1915-1921. doi: 10.1136/ijgc-2020-001641. Epub 2020 Oct 26.PMID: 33106271
275. Sassine D, Nasioudis D, Miller K, Chang R, Basaran D, Smith ES, Ehmann S, **Chi DS**. Acute pericarditis after transabdominal cardiophrenic lymph node dissection and pericardotomy during ovarian cancer debulking surgery: A case report. *Gynecol Oncol Rep*. 2020 Dec 11;35:100683. doi: 10.1016/j.gore.2020.100683. eCollection 2021 Feb.PMID: 33364288
276. Boerner T, Tanner E, Filippova O, Zhou QC, Iasonos A, Tew WP, O'Cearbhaill RE, Grisham RN, Gardner GJ, Sonoda Y, Abu-Rustum NR, Zivanovic O, Long Roche K, Afonso AM, Fischer M, **Chi DS**. Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. *Gynecol Oncol*. 2021 Jan;160(1):51-55. doi: 10.1016/j.ygyno.2020.10.042. Epub 2020 Nov 17.PMID: 3321389

277. Leitaio MM Jr, Zhou QC, Schiavone MB, Cowan RA, Smith ES, Iasonos A, Veith M, Rafizadeh M, Curran K, Ramesh B, Chang K, **Chi DS**, Sonoda Y, Brown AK, Cosin JA, Abu-Rustum NR, Martino MA, Mueller JJ, Long Roche K, Jewell EL, Broach V, Lambrou NC, Diaz JP, Zivanovic O. Prophylactic Negative Pressure Wound Therapy After Laparotomy for Gynecologic Surgery: A Randomized Controlled Trial. *Obstet Gynecol*. 2021 Feb 1;137(2):334-341. doi: 10.1097/AOG.0000000000004243. PMID: 33416292
278. Straubhar AM, Wolf JL, Zhou MQC, Iasonos A, Cham S, Wright JD, Long Roche K, **Chi DS**, Zivanovic O. Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events. *Gynecol Oncol*. 2021 Feb;160(2):438-444. doi: 10.1016/j.ygyno.2020.11.021. Epub 2020 Dec 4. PMID: 33272645
279. Oseledchuk A, Gemignani ML, Zhou QC, Iasonos A, Elahjji R, Adamou Z, Feit N, Goldfarb SB, Long Roche K, Sonoda Y, Goldfrank DJ, **Chi DS**, Saban SS, Broach V, Abu-Rustum NR, Carter J, Leitaio M, Zivanovic O. Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. *Int J Gynecol Cancer*. 2021 Feb;31(2):222-231. doi: 10.1136/ijgc-2020-001966. Epub 2020 Dec 3. PMID: 33273020
280. Boerner T, Walch HS, Nguyen B, Iasonos A, Zhou QC, Schultz N, Chui MH, Grisham RN, Tew WP, O'Cearbhaill RE, Aghajanian C, Zivanovic O, Abu-Rustum NR, Gardner GJ, Sonoda Y, **Chi DS**, Long Roche K. Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. *Gynecol Oncol*. 2021 Mar;160(3):696-703. doi: 10.1016/j.ygyno.2020.12.022. Epub 2020 Dec 30. PMID: 33386131
316. Ehmann S, Aviki EM, Sonoda Y, Boerner T, Sassine D, Jones DR, Park B, Cohen M, Rosenblum NG, **Chi DS**. Diaphragm hernia after debulking surgery in patients with ovarian cancer. *Gynecol Oncol Rep*. 2021 Mar 31;36:100759. doi: 10.1016/j.gore.2021.100759. eCollection 2021 May. PMID: 33869713
282. Boitano TKL, **Chi DS**, Copeland LJ, Straughn JM Jr. Standing on the shoulders of giants: Mentorship advice from leaders in the field. *Gynecol Oncol*. 2021 May;161(2):339-341. doi: 10.1016/j.ygyno.2021.01.017. Epub 2021 Jan 28. PMID: 33516530
283. Ehmann S, Park B, **Chi DS**. Minimally invasive repair of a left diaphragm hernia after debulking surgery for advanced ovarian cancer. *Gynecol Oncol Rep*. 2021 Feb 11;36:100713. doi: 10.1016/j.gore.2021.100713. eCollection 2021 May. PMID: 33732848
284. Filippova OT, Selenica P, Pareja F, Vahdatinia M, Zhu Y, Pei X, Riaz N, Long Roche K, **Chi DS**, Abu-Rustum NR, Ellenson LH, Reis-Filho JS, Zamarin D, Weigelt B. Molecular characterization of high-grade serous ovarian cancers occurring in younger

- and older women. *Gynecol Oncol*. 2021 May;161(2):545-552. doi: 10.1016/j.ygyno.2021.02.028. Epub 2021 Mar 3.PMID: 33674143
285. Gu S, Lheureux S, Sayad A, Cybulska P, Hogen L, Vyarvelska I, Tu D, Parulekar WR, Nankivell M, Kehoe S, **Chi DS**, Levine DA, Bernardini MQ, Rosen B, Oza A, Brown M, Neel BG. Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. *Proc Natl Acad Sci U S A*. 2021 Jun 22;118(25):e2026663118. doi: 10.1073/pnas.2026663118.PMID: 34161278
 286. Filippova OT, Tin AL, Alonso J, Vickers AJ, Tew WP, Gardner GJ, Sonoda Y, Roche KL, Zivanovic O, **Chi DS**, Shahrokni A. Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer. *Gynecol Oncol*. 2021 Jun;161(3):687-692. doi: 10.1016/j.ygyno.2021.03.016. Epub 2021 Mar 25.PMID: 33773807
 287. Manning-Geist BL, **Chi DS**, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, O'Cearbhaill RE, Abu-Rustum NR, Leitao MM Jr. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. *Gynecol Oncol*. 2021 Aug;162(2):345-352. doi: 10.1016/j.ygyno.2021.05.015. Epub 2021 May 25.PMID: 34045053
 288. Moukarzel LA, Braxton KF, Zhou QC, Pedra Nobre S, Iasonos A, Alektiar KM, Tew WP, Abu-Rustum NR, Leitao MM Jr, **Chi DS**, Mueller JJ. Non-exenterative surgical management of recurrent endometrial carcinoma. *Gynecol Oncol*. 2021 Aug;162(2):268-276. doi: 10.1016/j.ygyno.2021.05.020. Epub 2021 Jun 2.PMID: 34090704
 289. Zivanovic O, **Chi DS**, Zhou Q, Iasonos A, Konner JA, Makker V, Grisham RN, Brown AK, Nerenstone S, Diaz JP, Schroeder ED, Langstraat CL, Paroder V, Lakhman Y, Soldan K, Su K, Gardner GJ, Andikyan V, Guo J, Jewell EL, Long Roche K, Troso-Sandoval T, Lichtman SM, Moukarzel LA, Dessources K, Abu-Rustum NR, Aghajanian C, Tew WP, Beumer J, Sonoda Y, O'Cearbhaill RE. Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. *J Clin Oncol*. 2021 Aug 10;39(23):2594-2604. doi: 10.1200/JCO.21.00605. Epub 2021 May 21.PMID: 34019431
 290. Moukarzel LA, Casanova J, Filipe Cunha J, Paty PB, Pappou EP, Jewell E, **Chi DS**. Retroileal colorectal anastomosis after left-sided or transverse colectomy for advanced serous carcinoma of the ovary or uterus. *Gynecol Oncol Rep*. 2021 Jul 21;37:100834. doi: 10.1016/j.gore.2021.100834. eCollection 2021 Aug.PMID: 34368413
 291. Manning-Geist BL, **Chi DS**, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, O'Cearbhaill RE, Abu-Rustum NR, Leitao MM Jr. Quaternary and beyond cytoreduction:

- An updated and expanded analysis. *Gynecol Oncol Rep.* 2021 Aug 24;37:100851. doi: 10.1016/j.gore.2021.100851. eCollection 2021 Aug. PMID: 34485661
292. Basaran D, Boerner T, Suhner J, Sassine D, Liu Y, Grisham RN, Tew WP, Gardner GJ, Zivanovic O, Sonoda Y, Long Roche K, **Chi DS**, Abu-Rustum NR, Soff GA, Jewell EL. Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy. *Gynecol Oncol.* 2021 Oct;163(1):36-40. doi: 10.1016/j.ygyno.2021.07.030. Epub 2021 Jul 24. PMID: 34312001
 293. Aviki EM, Manning-Geist BL, Sokolowski SS, Newman T, Blinder VS, Chino F, Doyle SM, Liebhaber A, Gordhandas SB, Brown CL, Broach V, **Chi DS**, Jewell EL, Leitao MM Jr, Long Roche K, Mueller JJ, Sonoda Y, Zivanovic O, Gardner GJ, Abu-Rustum NR. Risk Factors for Financial Toxicity in Gynecologic Cancer Patients. *Am J Obstet Gynecol.* 2021 Dec 10:S0002-9378(21)02650-8. doi: 10.1016/j.ajog.2021.12.012. Online ahead of print. PMID: 34902319
 294. Feinberg J, Carthew K, Webster E, Chang K, McNeil N, **Chi DS**, Long Roche K, Gardner G, Zivanovic O, Sonoda Y. Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study. *Int J Gynecol Cancer.* 2022 Feb;32(2):159-164. doi: 10.1136/ijgc-2021-002885. Epub 2021 Dec 29. PMID: 34969828
 295. Manning-Geist BL, Gordhandas SB, Giri DD, Iasonos A, Zhou Q, Girshman J, O'Cearbhaill RE, Zamarin D, Lichtman SM, Sabbatini PJ, Tew WP, Li K, McDonnell AS, Aviki EM, **Chi DS**, Aghajanian CA, Grisham RN. Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer. *Gynecol Oncol.* 2022 Jan;164(1):12-17. doi: 10.1016/j.ygyno.2021.10.087. Epub 2021 Nov 8. PMID: 34763937
 296. Vanguri R, Benhamida J, Young JH, Li Y, Zivanovic O, **Chi D**, Snyder A, Hollmann TJ, Mager KL. Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer. *Gynecol Oncol Rep.* 2022 Jan 7;39:100926. doi: 10.1016/j.gore.2022.100926. eCollection 2022 Feb. PMID: 35146104
 297. Carter J, Abu-Rustum NR, Saban S, Chen LY, Vickers AJ, Tin AL, Billanti G, Connors NA, Broach V, Brown CL, **Chi DS**, Gardner GJ, Goldfrank DJ, Jewell EL, Leitao MM Jr, Long Roche KC, Mueller JJ, Sonoda Y, Zivanovic O. Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. *JCO Clin Cancer Inform.* 2022 Feb;6:e2100154. doi: 10.1200/CCI.21.00154. PMID: 35239413
 298. Manning-Geist BL, Cowan RA, Schlappé B, Braxton K, Sonoda Y, Long Roche K, Leitao MM Jr, **Chi DS**, Zivanovic O, Abu-Rustum NR, Mueller JJ. Assessment of wound perfusion with near-infrared angiography: A prospective feasibility study. *Gynecol Oncol Rep.* 2022 Feb 3;40:100940. doi: 10.1016/j.gore.2022.100940. eCollection 2022 Apr. PMID: 35169608

299. Moukarzel LA, Ferrando L, Dopeso H, Stylianou A, Basili T, Pareja F, Da Cruz Paula A, Zoppoli G, Abu-Rustum NR, Reis-Filho JS, Long Roche K, Tew WP, **Chi DS**, Sonoda Y, Zamarin D, Aghajanian C, O'Cearbhaill RE, Zivanovic O, Weigelt B. Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. *Gynecol Oncol*. 2022 May;165(2):239-247. doi: 10.1016/j.ygyno.2022.02.022. Epub 2022 Mar 12. PMID: 35292180
300. Nguyen AQ, Ehmann S, Feinberg J, Tew WP, Carthew K, Sonoda Y, **Chi DS**. Multiple isolated ovarian cancer recurrences in the cervix and vagina after supracervical hysterectomy: A case report. *Gynecol Oncol Rep*. 2022 May 23;41:101006. doi: 10.1016/j.gore.2022.101006. eCollection 2022 Jun. PMID: 35663846
301. Sia TY, Manning-Geist B, Gordhandas S, Murali R, Marra A, Liu YL, Friedman CF, Hollmann TJ, Zivanovic O, **Chi DS**, Weigelt B, Konner JA, Zamarin D. Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. *Int J Gynecol Cancer*. 2022 Aug 1;32(8):1017-1024. doi: 10.1136/ijgc-2022-003430. PMID: 35545291
302. Manning-Geist B, Gordhandas S, Hodgson A, Zhou QC, Iasonos A, **Chi DS**, Ellenson L, Aghajanian CA, Abu-Rustum NR, Leitao M, Long K, Rubinstein MM, Sonoda Y, Alektiar K, Weigelt B, Zivanovic O, Grisham RN. Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation. *Int J Gynecol Cancer*. 2022 Dec 5;32(12):1576-1582. doi: 10.1136/ijgc-2022-003935. PMID: 36368707
303. Park KJ, Broach V, **Chi DS**, Linkov I, Stanczyk FZ, Patel P, Jotwani A, Pearce CL, Pike MC, Kauff ND. Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intrauterine Contraceptive System. *Cancer Epidemiol Biomarkers Prev*. 2022 Sep 2;31(9):1823-1829. doi: 10.1158/1055-9965.EPI-22-0217. PMID: 35700017
304. Manning-Geist B, Gordhandas S, Liu YL, Zhou Q, Iasonos A, Da Cruz Paula A, Mandelker D, Roche KL, Zivanovic O, Maio A, Kemel Y, **Chi DS**, O'Cearbhaill RE, Aghajanian C, Weigelt B, Chui MH, Grisham RN. MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma. *Clin Cancer Res*. 2022 Oct 14;28(20):4456-4465. doi: 10.1158/1078-0432.CCR-21-4183. PMID: 35443055
305. Manning-Geist B, Gordhandas S, Hodgson A, Zhou QC, Iasonos A, **Chi DS**, Ellenson L, Aghajanian CA, Abu-Rustum NR, Leitao M, Long K, Rubinstein MM, Sonoda Y, Alektiar K, Weigelt B, Zivanovic O, Grisham RN. Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation. *Int J Gynecol Cancer*. 2022 Dec 5;32(12):1576-1582. doi: 10.1136/ijgc-2022-003935. PMID: 36368707

306. Vázquez-García I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, Niyazov J, Ruiz AEB, Boehm KM, Bojilova V, Fong CJ, Funnell T, Grewal D, Havasov E, Leung S, Pasha A, Patel DM, Pourmaleki M, Rusk N, Shi H, Vanguri R, Williams MJ, Zhang AW, Broach V, **Chi DS**, Da Cruz Paula A, Gardner GJ, Kim SH, Lennon M, Long Roche K, Sonoda Y, Zivanovic O, Kundra R, Viale A, Derakhshan FN, Geneslaw L, Issa Bhaloo S, Maroldi A, Nunez R, Pareja F, Stylianou A, Vahdatinia M, Bykov Y, Grisham RN, Liu YL, Lakhman Y, Nikolovski I, Kelly D, Gao J, Schietinger A, Hollmann TJ, Bakhoun SF, Soslow RA, Ellenson LH, Abu-Rustum NR, Aghajanian C, Friedman CF, McPherson A, Weigelt B, Zamarin D, Shah SP. Ovarian cancer mutational processes drive site-specific immune evasion. *Nature*. 2022 Dec;612(7941):778-786. doi: 10.1038/s41586-022-05496-1. Epub 2022 Dec 14. PMID: 36517593
307. Moukarzel LA, Nguyen N, Zhou Q, Iasonos A, Schiavone MB, Ramesh B, **Chi DS**, Sonoda Y, Abu-Rustum NR, Mueller JJ, Long Roche K, Jewell EL, Broach V, Zivanovic O, Leitao MM Jr. Association of bowel preparation with surgical-site infection in gynecologic oncology surgery: Post-hoc analysis of a randomized controlled trial. *Gynecol Oncol*. 2023 Jan;168:100-106. doi: 10.1016/j.ygyno.2022.11.003. Epub 2022 Nov 21. PMID: 36423444
308. Liu YL, Manning-Geist BL, Knezevic A, Deng L, Bromberg M, Funt SA, Meisel JL, Zivanovic O, Roche KL, Sonoda Y, Gardner GJ, Grisham RN, O'Cearbhaill RE, Tew WP, Abu-Rustum NR, **Chi DS**, Aghajanian C, Feldman DR. Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management. *Gynecol Oncol*. 2023 Mar;170:93-101. doi: 10.1016/j.ygyno.2022.12.022. Epub 2023 Jan 18. PMID: 36669327
309. Ehmann S, Shay K, Zhou Q, Iasonos A, Sonoda Y, Gardner GJ, Long Roche K, Zammarrelli WA 3rd, Yeoushoua E, O'Cearbhaill RE, Zivanovic O, **Chi DS**. Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study. *Gynecol Oncol*. 2023 Feb;169:118-124. doi: 10.1016/j.ygyno.2022.12.009. Epub 2022 Dec 22. PMID: 36565685
310. Kahn R, Filippova O, Gordhandas S, An A, Straubhar AM, Zivanovic O, Gardner GJ, O'Cearbhaill RE, Tew WP, Grisham RN, Sonoda Y, Long Roche K, Abu-Rustum NR, **Chi DS**. Ten-year conditional probability of survival for patients with ovarian cancer: A new metric tailored to Long-term survivors. *Gynecol Oncol*. 2023 Feb;169:85-90. doi: 10.1016/j.ygyno.2022.11.030. Epub 2022 Dec 13. PMID: 36521353
311. Praiss AM, Zhou Q, Iasonos A, Moukarzel L, Dessources K, Soldan K, Su K, Sonoda Y, Roche KL, Gardner GJ, Troso-Sandoval T, Tew WP, Grisham RN, **Chi DS**, O'Cearbhaill RE, Zivanovic O. Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial. *Gynecol Oncol*. 2023 Apr;171:23-30. doi: 10.1016/j.ygyno.2023.02.003. Epub 2023 Feb 16. PMID: 36804618

312. Straubhar AM, Zhou Q, Iasonos A, Clarke-Pearson DL, Cliby WA, Hoffman MS, **Chi DS**. Cross-sectional survey of surgical practices among gynecologic oncologists in the United States. *Gynecol Oncol*. 2023 May;172:36-40. doi: 10.1016/j.ygyno.2023.03.004. Epub 2023 Mar 16. PMID: 36933401
313. Manning-Geist BL, Kahn RM, Nemirovsky D, Girshman J, Laibangyang A, Gordhandas S, Iasonos A, Chui MH, Long Roche K, Zivanovic O, **Chi DS**, Aghajanian C, Grisham RN. Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies. *Cancer*. 2023 Jul 1;129(13):2004-2012. doi: 10.1002/cncr.34753. Epub 2023 Mar 23. PMID: 36951509
314. Sia TY, Gordhandas SB, Birsoy O, Kemel Y, Maio A, Salo-Mullen E, Sheehan M, Hensley ML, Rubinstein M, Makker V, Grisham RN, O'Cearbhaill RE, Roche KL, Mueller JJ, Leitao MM Jr, Sonoda Y, **Chi DS**, Abu-Rustum NR, Berger MF, Ellenson LH, Latham A, Stadler Z, Offit K, Aghajanian C, Weigelt B, Mandelker D, Liu YL. Germline drivers of gynecologic carcinosarcomas. *Gynecol Oncol*. 2023 Jul;174:34-41. doi: 10.1016/j.ygyno.2023.04.024. Epub 2023 May 5. PMID: 37149903
315. Feinberg J, Zivanovic O, Hannon M, McCreedy T, Desai P, Kim SH, Aviki EM, Mueller JJ, Jewell EL, Roche KL, Gardner GJ, **Chi DS**, Sonoda Y, Brown CL, Abu-Rustum NR, Cracchiolo JR, Leitao MM Jr, Broach V. Patient-reported symptoms after minimally invasive hysterectomy and association with postoperative complications. *Gynecol Oncol*. 2023 Aug;175:163-168. doi: 10.1016/j.ygyno.2023.06.011. Epub 2023 Jun 28. PMID: 37390597
316. Horvat N, Causa Andrieu P, Meier A, Ji X, Lakhman Y, Soslow R, Allison D, Gangai N, Rodriguez L, Kattan MW, **Chi DS**, Hricak H. A preoperative nomogram incorporating CT to predict the probability of ovarian clear cell carcinoma. *Gynecol Oncol*. 2023 Sep;176:90-97. doi: 10.1016/j.ygyno.2023.06.579. Epub 2023 Jul 19. PMID: 37478617
317. Sia TY, Tew WP, Purdy C, **Chi DS**, Menzin AW, Lovecchio JL, Bookman MA, Cohn DE, Teoh DG, Friedlander M, Bender D, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray HJ, Secord AA, Van Le L, Lichtman SM. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study. *Gynecol Oncol*. 2023 Jun;173:130-137. doi: 10.1016/j.ygyno.2023.03.018. Epub 2023 May 4. PMID: 37148580
318. Kahn RM, McMinn E, Yeoshoua E, Boerner T, Zhou Q, Iasonos A, Long Roche K, Zivanovic O, Gardner GJ, Sonoda Y, O'Cearbhaill RE, Grisham RN, Tew W, Jones D, Huang J, Park BJ, Abu-Rustum NR, **Chi DS**. Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study. *Gynecol Oncol*. 2023 Mar;170:46-53. doi: 10.1016/j.ygyno.2022.12.023. Epub 2023 Jan 6. PMID: 36621269

319. Andrieu PC, Nikolovski I, Juluru K, Sadowski E, Gangai N, Zheng J, Capanu M, Praiss AM, Nougaret S, Shinagare AB, Ma W, Torrisi JM, Sonoda Y, **Chi DS**, Lakhman Y. Synoptic Reporting for Pretreatment CT Examinations in Patients With Advanced Ovarian Cancer: Impact on Documentation of Disease Sites and Physician Satisfaction. Memorial Sloan Kettering Cancer Center Team Ovary. *AJR Am J Roentgenol*. 2023 Jul 12. doi: 10.2214/AJR.23.29096. Online ahead of print. PMID: 37436033
320. Sia TY, Manning-Geist BL, Ehmann S, Lavery JA, Luardo C, Praiss A, Iasonos A, Sonoda Y, Grisham RN, Liu YL, Broach V, Zivanovic O, Long Roche K, Gardner GJ, **Chi DS** Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study. *Gynecol Oncol*. 2023 Sep;176:69-75. doi: 10.1016/j.ygyno.2023.07.006. Epub 2023 Jul 14. PMID: 37454565
321. Woo S, Andrieu PC, Abu-Rustum NR, Broach V, Zivanovic O, Sonoda Y, **Chi DS**, Aviki E, Ellis A, Carayon P, Hricak H, Vargas HA. Bridging Communication Gaps Between Radiologists, Referring Physicians, and Patients Through Standardized Structured Cancer Imaging Reporting: The Experience with Female Pelvic MRI Assessment Using O-RADS and a Simulated Cohort Patient Group. *Acad Radiol*. 2024 Apr;31(4):1388-1397. doi: 10.1016/j.acra.2023.08.005. Epub 2023 Sep 1. PMID: 37661555
322. Rios-Doria E, Momeni-Boroujeni A, Friedman CF, Selenica P, Zhou Q, Wu M, Marra A, Leitao MM Jr, Iasonos A, Alektiar KM, Sonoda Y, Makker V, Jewell E, Liu Y, **Chi D**, Zamarin D, Abu-Rustum NR, Aghajanian C, Mueller JJ, Ellenson LH, Weigelt B. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma. *Gynecol Oncol*. 2023 Jul;174:262-272. doi: 10.1016/j.ygyno.2023.05.059. Epub 2023 May 26. PMID: 37245486
323. Sia TY, Maio A, Kemel YM, Arora KS, Gordhandas SB, Kahn RM, Salo-Mullen EE, Sheehan MA, Tejada PR, Bandlamudi C, Zhou Q, Iasonos A, Grisham RN, O'Cearbhaill RE, Tew WP, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, **Chi DS**, Latham AJ, Carlo MI, Murciano-Goroff YR, Will M, Walsh MF, Robson ME, Mandelker DL, Berger MF, Abu-Rustum NR, Brown CL, Offit K, Hamilton JG, Aghajanian C, Weigelt B, Stadler ZK, Liu YL. Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer. *JCO Precis Oncol*. 2023 Sep;7:e2300137. doi: 10.1200/PO.23.00137. PMID: 37738546
324. Wong BZY, Causa Andrieu PI, Sonoda Y, **Chi DS**, Aviki EM, Vargas HA, Woo S. Improving risk stratification of indeterminate adnexal masses on MRI: What imaging features help predict malignancy in O-RADS MRI 4 lesions? *Eur J Radiol*. 2023 Nov;168:111122. doi: 10.1016/j.ejrad.2023.111122. Epub 2023 Sep 28. PMID: 3780619

325. Praiss AM, Hirani R, Zhou Q, Iasonos A, Sonoda Y, Abu-Rustum NR, Leitao MM Jr, Long Roche K, Broach V, Gardner GJ, **Chi DS**, Zivanovic O. Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study. *Gynecol Oncol.* 2023 Dec;179:169-179. doi: 10.1016/j.ygyno.2023.10.013. Epub 2023 Nov 21. PMID: 37992548
326. Kahn RM, Selenica P, Boerner T, Roche KL, Xiao Y, Sia TY, Maio A, Kemel Y, Sheehan M, Salo-Mullen E, Breen KE, Zhou Q, Iasonos A, Grisham RN, O'Cearbhaill RE, **Chi DS**, Berger MF, Kundra R, Schultz N, Ellenson LH, Stadler ZK, Offit K, Mandelker D, Aghajanian C, Zamarin D, Sabbatini P, Weigelt B, Liu YL. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival. *Gynecol Oncol.* 2024 Jan;180:35-43. PMID: PMC10922242.
327. Boerner T, Lam C, Basaran D, Liu YL, Grisham RN, Tew WP, Long Roche K, Zivanovic O, Abu-Rustum NR, Gardner GJ, Sonoda Y, **Chi DS**, Soff G, Jewell E. Safety and feasibility of therapeutic anticoagulation for newly diagnosed venous thromboembolism in women who undergo neoadjuvant chemotherapy for advanced ovarian cancer. *Int J Gynecol Cancer.* 2024 Jan 5;34(1):113-121. PMID: PMC11265789.
328. Praiss AM, White C, Iasonos A, Selenica P, Zivanovic O, **Chi DS**, Abu-Rustum NR, Weigelt B, Aghajanian C, Girshman J, Park KJ, Grisham RN. Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes. *Gynecol Oncol.* 2024 Mar;182:32-38. PMID: PMC10960687.
329. Kahn RM, Ma X, Gordhandas S, Yeoshoua E, Ellis RJ, Zhang X, Aviki EM, Abu-Rustum NR, Gardner GJ, Sonoda Y, Zivanovic O, Long Roche K, Jewell E, Boerner T, **Chi DS**. Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact on patient travel in New York State. *Gynecol Oncol.* 2024 Mar;182:141-147. PMID: PMC10960664.
330. Kahn RM, Chang SJ, **Chi DS**. Extra-abdominal cytoreductive techniques in ovarian cancer: how far can (should) we go? *Int J Gynecol Cancer.* 2024 Mar 4;34(3):379-385. doi: 10.1136/ijgc-2023-004630.
331. Sia TY, Wan V, Finlan M, Zhou QC, Iasonos A, Zivanovic O, Sonoda Y, **Chi DS**, Long Roche K, Jewell E, Tew WP, O'Cearbhaill RE, Cohen S, Makker V, Liu YL, Friedman CF, Kyi C, Zamarin D, Gardner G. Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series. *Int J Gynecol Cancer.* 2024 Apr 1;34(4):594-601. PMID: PMC11108643.
332. Byrne M, Sia TY, Fong C, Khurram A, Waters M, Kemel YM, Zhou Q, Ranganathan M, Long Roche K, **Chi DS**, Saban S, Wu M, Varice N, Hamilton JG, Carrot-Zhang J,

333. Abu-Rustum NR, Iasonos A, Ellenson LH, Mandelker D, Weigelt B, Brown CL, Aghajanian C, Stadler Z, Liu YL. Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake. *Gynecol Oncol*. 2024 Apr;183:126-132. PMID: PMC11153006.
334. Leitaio MM Jr, Iasonos A, Tomberlin M, Moukarzel LA, Price H, Bennetti G, Ramesh B, **Chi DS**, Long Roche K, Sonoda Y, Al-Niami A, Mueller JJ, Gardner GJ, Broach V, Jewell EL, Kim S, Feinberg J, Abu-Rustum NR, Zivanovic O. ARIA II: a randomized controlled trial of near-infrared Angiography during Rectosigmoid resection and Anastomosis in women with ovarian cancer. *Int J Gynecol Cancer*. 2024 Jul 1;34(7):1098-1101. doi: 10.1136/ijgc-2024-005395.
335. Ehmann S, Lam C, Zhou Q, Iasonos A, Grisham RN, Tew WP, O'Cearbhaill RE, Long Roche K, Zivanovic O, Sonoda Y, **Chi DS**, Gardner GJ. Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer. *Gynecol Oncol*. 2024 Jul;186:104-109. doi: 10.1016/j.ygyno.2024.03.006. Epub 2024 Apr 18. PMID: 38640773.
336. Kahn RM, Boerner T, Kim M, Lam C, Gordhandas S, Yeoshoua E, Zhou QC, Iasonos A, Al-Niaimi A, Gardner GJ, Long Roche K, Sonoda Y, Zivanovic O, Grisham RN, Abu-Rustum NR, **Chi DS**. A pre-operative scoring model to estimate the risk of blood transfusion over an ovarian cancer debulking surgery (BLOODS score): a Memorial Sloan Kettering Cancer Center Team Ovary study. *Int J Gynecol Cancer*. 2024 Jul 1;34(7):1051-1059. doi: 10.1136/ijgc-2024-005660. PMID: 38950927; PMCID: PMC11237961.
337. Filippova OT, Boecking K, Broach V, Gardner GJ, Sonoda Y, **Chi DS**, Zivanovic O, Long Roche K. Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study. *Gynecol Oncol*. 2024 Aug;187:80-84. doi: 10.1016/j.ygyno.2024.05.009.
338. Manning-Geist BL, Sullivan MW, Zhou Q, Iasonos A, Selenica P, Stallworth C, Liu YL, Long Roche K, Gordhandas S, Aghajanian C, **Chi D**, O'Cearbhaill R, Grisham RN, Chui MH. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities. *Gynecol Oncol*. 2024 Sep;188:52-57. PMID: PMC11368654.
339. Andres S, Finch L, Iasonos A, Zhou Q, Girshman J, Chhetri-Long R, Green H, Jang D, O'Cearbhaill R, Kyi C, Cohen S, Friedman C, Makker V, **Chi DS**, Sonoda Y, Chiang S, Aghajanian C, Weigelt B, Grisham RN. Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer. *Gynecol Oncol*. 2024 Oct;189:30-36. doi:10.1016/j.ygyno.2024.06.026.

340. Finch L, Broach V, Feinberg J, Al-Niaimi A, Abu-Rustum NR, Zhou Q, Iasonos A, **Chi DS**. ChatGPT compared to national guidelines for management of ovarian cancer: Did ChatGPT get it right? - A Memorial Sloan Kettering Cancer Center Team Ovary study. *Gynecol Oncol*. 2024 Oct;189:75-79. PMID:PMC11402584.
341. Dagher C, Lim YH, Sonoda Y, Marshall L, Long Roche K, Jewell E, **Chi DS**, Gardner G, Broach V, Mueller JJ, Abu-Rustum NR, Leitao MM Jr. Oncologic and Perioperative Outcomes of Robot-Assisted Versus Conventional Laparoscopy for the Treatment of Clinically Uterine-Confined High-Grade Adenocarcinoma. *Ann Surg Oncol*. 2024 Dec;31(13):8934-8943. doi: 10.1245/s10434-024-16029-7.
342. Moufarrij S, Dagher C, Filippova OT, Zhou Q, Iasonos A, Abu-Rustum NR, Mueller JJ, Leitao MM, Sandhu J, Bochner B, Carter J, **Chi DS**, Sonoda Y. Five-year quality-of-life assessment by urinary diversion type after pelvic Exenterations. *Gynecol Oncol*. 2024 Dec;191:212-218. doi: 10.1016/j.ygyno.2024.10.016.
343. Graves S, Sullivan MW, Adkoli A, Zhou Q, Iasonos A, Selenica P, Aghajanian C, Liu YL, Tew W, Sonoda Y, Ellenson LH, **Chi D**, O'Cearbhaill RE, Weigelt B, Grisham RN. Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer. *Gynecol Oncol*. 2024 Dec 7;192:120-127. doi: 10.1016/j.ygyno.2024.11.011.
344. Hoffman M, Dunsmore V, Cliby W, **Chi D**, Wheeler S, Clarke-Pearson D. Surgical training of gynecologic oncology fellows: Long-term trends and implications for future education. *Gynecol Oncol*. 2024 Apr 30;184:254-258. doi: 10.1016/j.ygyno.2024.04.017. Online ahead of print.

2. Books, book chapters and reviews.

Books, Journal Supplements, DVDs, CD-ROMs Edited:

1. **Chi DS**. Ovarian Cancer National Alliance. Reviewed by Ovarian Cancer National Alliance. *Resources A Guide For Women Living With Ovarian Cancer*. Bristol-Myers Squibb, Doctors +Designers 2000.
2. Agre P, **Chi DS**, Sabbatini P. Ovarian Cancer: an interactive multimedia program. CD-ROM funded by SmithKline Beecham Pharmaceuticals. Produced by Memorial Sloan-Kettering Cancer Center, New York, NY, 2001.
3. Bristow RE, **Chi DS**. Surgery for Advanced Ovarian Cancer. Society of Gynecologic Oncology Educational DVD, 2008.
4. Abu-Rustum NR, Ramirez PT, **Chi DS**. The Second Edition of the Society of Gynecologic Oncologists Surgical Postgraduate Courses supplement. *Gynecol Oncol* 2008; 111(2): S1-S120.

5. Bristow RE, Karlan BY, **Chi DS**. Surgery for Ovarian Cancer: Principles and Practice, 2nd Edition. New York: Informa Healthcare, 2010.
6. Bristow RE, **Chi DS**. Radical and Reconstructive Gynecologic Cancer Surgery. New York: McGraw-Hill Education, 2015.
7. Bristow RE, Karlan BY, **Chi DS**. Surgery for Ovarian Cancer, 3rd Edition. Boca Raton: CRC Press Taylor & Francis Group, 2016.
8. **Chi DS**, Berchuck A, Dizon DS, Yashar CM. Principles and Practice of Gynecologic Oncology, 7th Edition. Philadelphia: Wolters Kluwer, 2017
9. Bristow RE, Karlan BY, **Chi DS**. Surgery for Ovarian Cancer, 4th Edition. Boca Raton: CRC Press Taylor & Francis Group, 2023.
10. **Chi DS**, Lakhi N, Colombo N. 50 Big Debates in Gynecologic Oncology. Cambridge: Cambridge University Press 2023.
11. **Chi DS**, Khabele D, Dizon DS, Yashar CM. Principles and Practice of Gynecologic Oncology, 8th Edition. Philadelphia: Wolters Kluwer, 2024

Textbook Chapters:

1. **Chi DS**, Lanciano RM, Kudelka A. Cervical Cancer. In Pazdur R, Coia L, Wagman L, Hoskins W (eds): Cancer Management: A Multidisciplinary Approach Third Edition. New York: PRR; 1999, pp 239-264.
2. **Chi DS**, Lanciano RM, Kudelka A. Cervical Cancer. In Pazdur R, Coia L, Wagman L, Hoskins W (eds): Cancer Management: A Multidisciplinary Approach Fourth Edition. New York: PRR; 2000, pp 361-386.
3. **Chi DS**, Hoskins WJ. Primary Surgical Management Of Ovarian Cancer. In Bartlett J (ed): Methods in Molecular Medicine: Ovarian Cancer. Totowa, New Jersey: Humana Press, Inc.; 2000, pp 75-88.
4. Hensley M, Alektiar K, **Chi D**. Ovarian and Fallopian Tube Cancer. In Barakat RR, Bevers M, Gershenson DM, Hoskins WJ (eds): The MD Anderson / Memorial Sloan-Kettering Handbook of Gynecologic Oncology. London: Martin Dunitz Publishers; 2000, pp 243-263.
5. **Chi DS**, Gallup DG. Surgical Principles in Gynecologic Oncology. In Hoskins WJ, Perez CA, Young RC (eds): Principles and Practice of Gynecologic Oncology, 3rd ed. Philadelphia: Lippincott, Williams & Wilkins; 2000, pp 245-264.

6. **Chi DS**, Hoskins WJ. Primary Surgical Management Of Advanced Epithelial Ovarian Cancer. Rubin and Sutton (eds) : Ovarian Cancer. Philadelphia: Lippincott, Williams and Wilkins; 2001, pp 241-257.
7. **Chi DS**, Mychalczak B, Hoskins WJ. Cancer of the Vulva-Vagina. In Bland K, Daly JM, Karakousis CP (eds): Surgical Oncology: Contemporary Principles and Practice. Stamford, Connecticut: Appleton & Lange, Simon & Schuster; 2001, pp 853-882.
8. **Chi DS**, Lanciano RM, Kudelka A. Cervical Cancer. In Pazdur R, Coia L, Wagman L, Hoskins W (eds): Cancer Management: A Multidisciplinary Approach Fifth Edition. New York: PRR; 2001, pp 359-384.
9. **Chi DS**, Mychalczak B, Hoskins WJ. Cancer of the Vulva-Vagina. In Bland KI, Daly JM, Karakousis C (eds.): Surgical Oncology: Contemporary Principles and Practice. New York: Mcgraw Hill; 2001, pp 853-882.
10. **Chi DS**, Lanciano RM, Kudelka A. Cervical Cancer. In Pazdur R, Coia LR, Hoskins WJ, Wagman LD, (eds): Cancer Management: A Multidisciplinary Approach Sixth Edition. New York: PRR; 2002, pp 387-414.
11. Husain A, Daud A, **Chi D**. Management of Recurrent Cervical Cancer. In Markman M (ed): Atlas of Cancer. Philadelphia: Lippincott Williams & Wilkins, 2003, pp 73-78.
12. **Chi DS**, Lanciano RM, Kudelka A. Cervical Cancer. In Pazdur R, Coia LR, Hoskins WJ, Wagman LD, (eds): Cancer Management: A Multidisciplinary Approach Seventh Edition. New York: PRR; 2003, pp 419-448.
13. **Chi DS**, Abu-Rustum NR, Hoskins WJ. Cancer of the Cervix, In Rock JA, Jones HW, (eds): TeLinde's Operative Gynecology Ninth Edition. Philadelphia: Lippincott, Williams and Wilkins; 2003, pp 1373-1444.
14. Levine DA, Bochner BH, **Chi DS**. Pelvic Exenteration. In Levine DA, Barakat RR, Hoskins WJ, (eds): Atlas of Procedures in Gynecologic Oncology. United Kingdom: Martin Dunitz; 2003, pp 81-101
15. **Chi DS**, Lanciano RM, Kudelka A. Cervical Cancer. In Pazdur R, Coia LR, Hoskins WJ, Wagman LD, (eds): Cancer Management: A Multidisciplinary Approach Eighth Edition. New York: PRR; 2004, pp 419-451.
16. **Chi DS**, Gallup DG. Surgical Principles in Gynecologic Oncology. In Hoskins WJ, Perez CA, Young RC (eds). Barakat RR, Markman M, Randall ME (associate eds): Principles and Practice of Gynecologic Oncology, 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2005, pp 311-331.
17. **Chi DS**, Lanciano RM, Kudelka A. Cervical Cancer. In Pazdur R, Coia LR, Hoskins WJ, Wagman LD, (eds): Cancer Management: A Multidisciplinary Approach Ninth Edition.

New York: PRR; 2005, pp 445-479.

18. Sonoda Y, **Chi DS**, Barakat RR. In Cytoreductive Surgery: Intestinal Tract and Omentum. In Bristow RE and Karlan KY (eds): Surgery for Ovarian Cancer: Principles and Practice. United Kingdom: Taylor & Francis; 2006 pp 195-260.
19. **Chi DS**, Perez CA, Lanciano RM, Kavanagh J. Cervical Cancer. In Pazdur R, Coia LR, Hoskins WJ, Wagman LD, (eds): Cancer Management: A Multidisciplinary Approach Tenth Edition. Lawrence, CMP Media LLC; 2007, pp 441-470.
20. **Chi DS**, Kauff ND. Cancer of the ovary, Peritoneum, and Fallopian Tube. In ACOG (eds): Precise Oncology. Third Edition. American College of Obstetricians and Gynecologists. Danvers MA: Copyright Clearance Center; 2007, pp 88-100.
21. Leitao MM, **Chi DS**. Surgical Procedures in Gynecologic Oncology. In: Fishman D (ed). Requisites in Ob/Gyn: Gynecologic Oncology. Mosby; Philadelphia, PA. 2007
22. **Chi DS**, Perez CA, Kavanagh J. Cervical Cancer. In Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, (eds): Cancer Management: A Multidisciplinary Approach Eleventh Edition. Lawrence, CMP Media LLC; 2008, pp 465-496.
23. Eisenhauer EL, Leitao MM Jr, **Chi DS**. Surgical Cytoreduction. In Levine DA, Barakat RR, Abu-Rustum NR, (eds): Atlas of Procedures in Gynecologic Oncology, Second Edition. United Kingdom: Informa Healthcare; 2008, pp 57-92
24. Levine DA, Bochner BH, **Chi DS**. Pelvic Exenteration. In Levine DA, Barakat RR, Abu-Rustum NR, (eds): Atlas of Procedures in Gynecologic Oncology, Second Edition. United Kingdom: Informa Healthcare; 2008, pp 93-116
25. Diaz JP, Boland PJ, **Chi DS**, Abu-Rustum NR. Extended Pelvic Resection. In Levine DA, Barakat RR, Abu-Rustum NR, (eds): Atlas of Procedures in Gynecologic Oncology, Second Edition. United Kingdom: Informa Healthcare; 2008, pp 137-144
26. Diaz JP, **Chi DS**. Hand-Assisted Laparoscopic Splenectomy. In Levine DA, Barakat RR, Abu-Rustum NR, (eds): Atlas of Procedures in Gynecologic Oncology, Second Edition. United Kingdom: Informa Healthcare; 2008, pp 267-270
27. Eitan R, **Chi DS**. Video-Assisted Thoracoscopy. In Covens AL and Kupets R (eds): Laparoscopic Surgery for Gynecologic Oncology. New York: McGraw Hill Medical, New York; 2009, pp 123-129.
28. Mourton SM, Caceres A, Pusic AL, **Chi DS**. Cervical Cancer: Surgical Options for Recurrent Disease. In Dizon DS, Abu-Rustum NR (eds): Gynecologic Tumor Board. Sudbury, MA: Jones and Bartlett Publishers; 2009, pp 165-173.

29. Palayekar MJ, **Chi DS**. Evaluation and Treatment of Gynecologic Cancer. In Stubblefield MD, O'Dell MW (eds): Cancer Rehabilitation Principles and Practice. Demos Medical Publishing, LLC; 2009, pp 279-289.
30. **Chi DS**, Gallup DG, Bristow RE. Surgical Principles in Gynecologic Oncology. In Barakat RR, Markman M, Randall ME (eds): Principles and Practice of Gynecologic Oncology, 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2009, pp 269-287.
31. Eitan R, **Chi DS**. Secondary Cytoreduction in the Treatment of Recurrent Ovarian Cancer. In Bristow RE, Armstrong DK (eds): Early Diagnosis and Treatment of Cancer: Ovarian Cancer. Philadelphia: Saunders Elsevier; 2009, pp 179-191.
32. Eitan R, **Chi DS**. Video-Assisted Thoracoscopy. In Ayhan A, Gultekin M, Dursun P (eds): Textbook of Gynaecological Oncology. Ankara, Turkey: Gunes Publishing; 2009, pp 333-334.
33. Eitan R, **Chi DS**. Secondary Cytoreduction in the Treatment of Recurrent Ovarian Cancer: Pro. In Ayhan A, Gultekin M, Dursun P (eds): Textbook of Gynaecological Oncology. Ankara, Turkey: Gunes Publishing; 2009, pp 500-502.
34. Diaz JP, **Chi DS**. The Role of Video-Assisted Thoracic Surgery (VATS) and Intrathoracic Cytoreduction in gynecologic Malignancies. In Yildirm Y (ed): Cytoreductive Surgery in Gynecologic Oncology: A Multidisciplinary Approach. Kerala, India: Transworld Research Network; 2010, pp 201-212.
35. Sonoda Y, **Chi DS**, Barakat RR. Cytoreductive Surgery: Intestinal Tract and Omentum. In Bristow RE, Karlan BY, Chi DS (eds): Surgery for Ovarian Cancer: Principles and Practice, 2nd ed. New York: Informa Healthcare; 2010, pp 140-164.
36. Bristow RE, **Chi DS**, Secondary Cytoreductive Surgery. In Bristow RE, Karlan BY, Chi DS (eds): Surgery for Ovarian Cancer: Principles and Practice, 2nd ed. New York: Informa Healthcare; 2010, pp 218-234.
37. Zivanovic O, **Chi DS**, Karlan BY. Advanced Cytoreductive Surgery Program Development: Building a Cytoreductive Team. In Bristow RE, Karlan BY, Chi DS (eds): Surgery for Ovarian Cancer: Principles and Practice, 2nd ed. New York: Informa Healthcare; 2010, pp 291-300.
38. Eitan R, **Chi DS**. Video-Assisted Thoracic Surgery. In: Ayhan A, Reed N, Gultekin M (eds). Textbook of Gynaecological Oncology, 2nd Edition. Ankara, Turkey: Gunes Publishing; 2011, pp 711-712.
39. Eitan R, **Chi DS**. Secondary Cytoreduction in the Treatment of Recurrent Ovarian Cancer. In: Ayhan A, Reed N, Gultekin M (eds). Textbook of Gynaecological Oncology, 2nd Edition. Ankara, Turkey: Gunes Publishing. 2011, pp 985-987.

40. Tanner EJ, Khoury-Collado F, **Chi DS**. Cytoreductive Procedures. In: Karlan BY, Bristow RE, Li AJ (eds) *Gynecologic Oncology: Clinical Practice and Surgical Atlas*. New York: McGraw-Hill Companies, Inc; 2012, pp 585-608.
41. **Chi DS**, Bristow RE, Cibula D. Surgical Principles in Gynecologic Oncology. In: Barakat RR, Berchuck A, Markman M, Randall ME. *Principles and Practice of Gynecologic Oncology*, Sixth Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2013, pp 190-209.
42. Andikyan V, Khoury-Collado F, Bochner BH, **Chi DS**. Pelvic exenteration. In: Abu-Rustum NR, Barakat RR, Levine DA (eds.). *Atlas of Procedures in Gynecologic Oncology*, 3rd edition. London: CRC Press; 2013, pp 97-120.
43. Andikyan V, Khoury-Collado F, Boland PJ, **Chi DS**. Extended pelvic resections and laterally extended endopelvic resections. In: Abu-Rustum NR, Barakat RR, Levine DA (eds.). *Atlas of Procedures in Gynecologic Oncology*, 3rd edition. London: CRC Press; 2013, pp 147-154.
44. Sehouli J, Eisenhauer EL, Leitao Jr. MM, **Chi DS**. Surgical cytoreduction. In: Abu-Rustum NR, Barakat RR, Levine DA (eds.). *Atlas of Procedures in Gynecologic Oncology*, 3rd edition. London: CRC Press; 2013, pp 65-100.
45. Diaz JP, **Chi DS**. Hand-assisted laparoscopic splenectomy. In: Abu-Rustum NR, Barakat RR, Levine DA (eds.). *Atlas of Procedures in Gynecologic Oncology*, 3rd edition. London: CRC Press; 2013, pp 278-281.
46. Long KC, **Chi DS**. Ovarian Cancer: Surgical Considerations. In: Lichtman S, Audisio R. *Management of Gynecological Cancers in Older Women*. London: Springer-Verlag; 2013, pp 151-170.
47. Schorge JO, **Chi DS**. Surgical Management of Ovarian Cancer. In: Odunsi K, Pejovic T (eds). *Gynecologic Cancers, A Multidisciplinary Approach to Diagnosis and Management*. New York: Demos Medical; 2013, pp 115-126.
48. Eitan R, de Graeff A, **Chi DS**. Bowel Obstruction in Ovarian Cancer: To Operate or Not? In: Ledermann JA, Creutzberg CL, and Quinn M (eds). *Controversies in the Management of Gynecologic Cancers*. London: Springer-Verlag; 2014, pp 197-202.
49. Eisenhauer EL, **Chi DS**. Extended Surgery for Advanced Ovarian Cancer. In: Patel HRH, Mould T, Joseph JV, Delaney CP (eds). *Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances*. London: Springer-Verlag; 2015, pp 429-440.
50. St. Clair CM, Khoury-Collado F, **Chi DS**. Timing of Cytoreductive Surgery in the Treatment of Advanced Epithelial Ovarian Carcinoma. In: Birrer MJ, Ceppi L (eds). *Translational Advances in Gynecologic Cancers*. London: Elsevier Inc; 2017 pp 59-78.

List of Significant Publications/Reviews/Monographs/Videos:

1. **Chi DS**, Hoskins WJ. Ovarian cancer screening: When and how to use available screening methods. Medscape Women's Health 1996; 1 (11).
2. **Chi DS**, Curtin JP, Hoskins WJ. Primary surgical management and intraperitoneal chemotherapy of ovarian cancer. Oncologia Clinica 1997; 2:67-76.
3. Boente MP, **Chi DS**, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998; 25:326-334.
4. **Chi DS**. The diagnosis and management of vulvar cancer. Medscape Women's Health 1998; 1(2).
5. **Chi DS**. The Diagnosis and management of vulvar cancer. Prim Care Update Ob/Gyn 1999;6:24-32.
6. **Chi DS**, Curtin JP. Gynecologic cancer and laparoscopy. Obstet Gynecol Clin North Am 1999;26(1):201-15.
7. Abu Rustum NR, **Chi DS**, Curtin JP. Epithelial ovarian cancer. Curr Probl Surg 1999;36(1):1-53.
8. **Chi DS**. Laparoscopy in gynecologic malignancies. Oncology 1999;13:773-782.
9. **Chi DS**, Gemignani M, Curtin JP, Hoskins WJ. Long-Term experience in the surgical management of cancer of the uterine cervix. Semin Surg Oncol 1999;17:161-167.
10. Hoskins WJ, **Chi DS**, Boente MP, Rubin SC. State of the art surgical management of ovarian cancer. Cancer Research Therapy and Control 1999;9:373-382.
11. **Chi DS**, Sabbatini P. Advanced ovarian cancer. Current Treatment Options in Oncology 2000;1:139-146.
12. **Chi DS**, Hoskins WJ. Sampling para-aortic lymph nodes in gynecologic cancers. CME J of Gynecol Oncol 2000; 5(2):111-117.
13. **Chi DS**, Barakat RR. Surgical management of advanced or recurrent endometrial cancer. Surg Clin North Am. 2001;81(4):885-96.
14. Leita Jr. MM, **Chi DS**. Recurrent cervical cancer. Current Treatment Options in Oncology: Gynecologic Tumors 2002;3(2):105-111.
15. McCreath WA, **Chi DS**. Surgical cytoreduction in ovarian cancer. Oncology. 2004;18(5):645-652.

16. Leiser AL, Soslow RA, **Chi DS**. Borderline ovarian tumors. *Postgraduate Obstetrics and Gynecology* 2004;24:22-30.
17. Juretzka M, Sonoda Y, **Chi DS**. Update of surgical treatment for endometrial cancer. *Expert Rev Anticancer Ther* 2005;5(1):113-21.
18. McCreath WA, Salom E, **Chi DS**. Cervical Cancer: Current Management of Early/Late Disease. *Surg Oncol Clin North Am* 2005;14:249-266.
19. Eitan R, **Chi DS**. Successful pregnancies after fertility preserving treatment of ovarian carcinoma. *Nature Clinical Practice Oncology* 2005;2:647-651.
20. **Chi DS**, Monemvasitis G, Awtrey CS, Mourton SM. Surgery for recurrent gynecologic malignancies. *J KAMA* 2005;11(1):39-43.
21. Leitao MM, **Chi DS**. Fertility-Sparing Options for Patients with Gynecologic Malignancies. *Oncologist* 2005;10(8):613-22.
22. Leitao MM, **Chi DS**. Cytoreductive surgery for ovarian cancer. *Postgraduate Obstetrics and Gynecology* 2004;24(10):1-8.
23. Diaz JP, **Chi DS**. Hand-assisted laparoscopic splenectomy for isolated ovarian cancer recurrence. *Gynecol Oncol.* 2007;104(2 Suppl):S17-9.
24. Eisenhauer EL, **Chi DS**. Liver mobilization and diaphragm peritonectomy/resection. *Gynecol Oncol.* 2007;104(2 Suppl):S25-8.
25. Caceres A, **Chi DS**, Boland PJ, Barakat RR, Abu-Rustum NR. Superior pubic rami resection for isolated recurrent uterine cancer. *Gynecol Oncol.* 2007;104(2 Suppl):45-7.
26. Eisenhauer EL, Bristow RE, **Chi DS**. Neoadjuvant Chemotherapy for Ovarian Cancer: Pro vs. Con. *The Women's Oncology Review* 2006;6(1-2):27-35.
27. **Chi DS**, Diaz JP, Jarnagin WR. Distal partial gastrectomy and gastrojejunal anastomosis for recurrent ovarian cancer. *Gynecol Oncol* 2007;104(2):S45-47.
28. **Chi DS**, Caceres A, Boland PJ. Extended pelvic resection of iliacus muscle and femoral nerve for isolated recurrent uterine cancer. *Gynecol Oncol.* 2007;104(2 Suppl):48-9.
29. **Chi DS**, Roberts CA, Abu-Rustum NR. Retroperitoneal lymph node dissection. *Gynecol Oncol.* 2007;104(2 Suppl):37-9.
30. Leitao Jr. MM, **Chi DS**. Operative management of primary epithelial ovarian cancer. *Curr Oncol Rep.* 2007 (6):478-84.

31. Palayekar MJ, **Chi DS**. Pre and postoperative pleural effusions in ovarian malignancies. International pleural newsletter 2008;6:13-14.
32. Zivanovic O, **Chi DS**. Surgical resection and reconstruction for advanced and recurrent gynecologic malignancies. Expert Rev Obstet Gynecol 2008;3(5):677-690.
33. Kehoe SM, Eisenhauer EA, **Chi DS**. Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy and distal pancreatectomy. Gynecol Oncol 2008;111(2):S51-S55.
34. Schaberg FJ Jr, Prinz RA, Chen EL, Caceres A, **Chi DS**, Ryder BA, Ng T, Santi Aragona M, Wotkowicz C, Libertino JA. Incidental findings at surgery – part 2. Curr Probl Surg. 2008;45(6):388-4395.
35. Schaberg FJ Jr, Prinz RA, Chen EL, Caceres A, **Chi DS**, Ryder BA, Ng T, Santi Aragona M, Wotkowicz C, Libertino JA. Incidental findings at surgery – part 2. In brief. Curr Probl Surg. 2008;45(6):384-5.
36. **Chi DS**, Schwartz P. SGO Fight Night Debate Neoadjuvant Chemotherapy or Radical Cytoreduction for Patients with Ovarian Cancer. Gynecol Oncol. 2008;111(3):391-9.
37. Leitaio MM, **Chi DS**. Surgical Management of Recurrent Ovarian Cancer. Semin Oncol. 2009;36(2):106-11.
38. Zivanovic O, Aldini A, Carlson JW, **Chi DS**. Advanced cytoreductive surgery: American perspective. Gynecol Oncol. 2009;114(2 Suppl):S3-9.
39. Finley DJ, Abu-Rustum NR, **Chi DS**, Flores R. Reconstructive techniques after diaphragm resection. Thoracic Surgery Clinics; Surgical Conditions of the Diaphragm. 2009;19(4):531-535.
40. Barlin JN, Bristow RE, **Chi DS**. The role of secondary cytoreduction in recurrent ovarian cancer. Therapy 2010;7(3):249-256.
41. Shih K, **Chi DS**. Maximal cytoreductive effort in epithelial ovarian cancer surgery. Journal of Gynecologic Oncology 2010;21(2): 75-80.
42. Bou Zgheib N, Silver D, **Chi DS**. Clinical approach to diagnosis and management of Ovarian, Fallopian Tube, and Peritoneal Carcinoma. Surgical Pathology Clinics 2011;4(1):261-274.
43. Khoury-Collado F, **Chi DS**. Recent surgical management of ovarian cancer. J Obstet Gynaecol Res. 2011;37(5):379-82

44. Schorge JO, Eisenhauer EE, **Chi DS**. Current surgical management of ovarian cancer. *Hematol Oncol Clin North Am*. 2012;26(1):93-109.
45. Porcel JM, Diaz JP, **Chi DS**. Clinical implications of pleural effusions in ovarian cancer. *Respirology*. 2012;17: 1060-1067.
46. Shih K, **Chi DS**. Surgery for Recurrent Ovarian Cancer. Up to Date. 2013.
47. Polcher M, Zivanovic O, **Chi DS**. Cytoreductive Surgery for Advanced Ovarian Cancer. Women's Health Peer Review Report. *Womens Health (Lond Engl)*. 2014;10(2):179-90.
48. Jarvis TR, Xie D, **Chi DS**, Temple LK, Boland PJ, Sandhu JS. Voiding dysfunction after non-genitourinary radical pelvic surgery. *Current Bladder Dysfunction Reports* 2014; 9(3): 234-241.
49. Abu-Rustum N, **Chi D**, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AK. Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. *Gynecol Oncol*. 2014;134(1):6-9
50. Narasimhulu DM, Khoury-Collado F, **Chi DS**. Radical Surgery in Ovarian Cancer. *Curr Oncol Rep* (2015) 17:16.
51. Lakhman Y, Nougaret S, Micco M, Scelzo C, Vargas HA, Sosa RE, Sutton EJ, **Chi DS**, Hricak H, Sala E. Role of MR Imaging and FDG PET/ CT in Selection and Follow-up of Patients Treated with Pelvic Exenteration for Gynecologic Malignancies. *Radiographics* 2015 Jul-Aug;35(4):1295-313.
52. Chang SJ, Bristow RE, **Chi DS**, Cliby WA. Role of Aggressive Surgical Cytoreduction in Advanced Ovarian Cancer. *J Gynecol Oncol* 2015 Vol. 26, No. 4:336-342
52. Cowan RA, O'Cearbhaill RE, Gardner GJ, Levine DA, Roche KL, Sonoda Y, Zivanovic O, Tew WP, Sala E, Lakhman Y, Vargas Alvarez HA, Sarasohn DM, Mironov S, Abu-Rustum NR, **Chi DS**. Is It Time to Centralize Ovarian Cancer Care in the United States? *Ann Surg Oncol*. 2016 Mar;23(3):989-93. doi: 10.1245/s10434-015-4938-9. Epub 2015 Oct 28. Review.
PMID:26511267
53. Leary A, Cowan R, **Chi D**, Kehoe S, Nankivell M. Primary Surgery or Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: The Debate Continues....*Am Soc Clin Oncol Educ Book*. 2016;35:153-62. doi: 10.14694/EDBK_160624. PMID: 27249696
54. Cowan RA, O'Cearbhaill RE, Zivanovic O, **Chi DS**. Current Status and Future Prospects of Hyperthermic Intraoperative Intraperitoneal Chemotherapy (HIPEC) Clinical Trials in Ovarian Cancer. *Int J Hyperthermia*. 2017 Jan 16:1-21. PMID:28092994

55. Cowan RA, **Chi DS**. Point/Counterpoint: Primary Debulking Surgery vs Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer. *Oncology (Williston Park)*. 2017 Jun 15;31(6):453-7. PMID: 28620901
56. Morano WF, Khalili M, **Chi DS**, Bowne WB, Esquivel J. Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions-A systematic review. *J Surg Oncol*. 2018 Feb;117(2):245-259. doi: 10.1002/jso.24813. Epub 2017 Nov 9. Review. PMID:29120491
57. Zivanovic O, **Chi DS**, Filippova O, Randall LM, Bristow RE, O'Cearbhaill RE. It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. *Gynecol Oncol*. 2018 Dec;151(3):555-561. doi: 10.1016/j.ygyno.2018.09.007. Epub 2018 Sep 22. Review. PMID: 30249527
58. Straubhar A, **Chi DS**, Long Roche K. Update on the role of surgery in the management of advanced epithelial ovarian cancer. *Clin Adv Hematol Oncol*. 2020 Nov;18(11):723-731.PMID: 33406064
59. Ehmann S, Zivanovic O, **Chi DS**. Why was GOG-0213 a negative trial? *J Gynecol Oncol*. 2021 Jan;32(1):e19. doi: 10.3802/jgo.2021.32.e19. Epub 2020 Dec 2.PMID: 33300314
60. Boerner T, Zivanovic O, **Chi DS**. Narrative review of cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases in ovarian cancer. *J Gastrointest Oncol*. 2021 Apr;12(Suppl 1):S137-S143. doi: 10.21037/jgo-20-274.PMID: 33968434
61. Chang SJ, Fotopoulou C, Bristow RE, **Chi DS**, Cliby WA.Rectosigmoid resection by gynecologic oncologists versus colorectal surgeons: as long as it catches the mouse, does the color of the cat matter? *J Gynecol Oncol*. 2021 May;32(3):e51. doi: 10.3802/jgo.2021.32.e51.PMID: 33825361
62. Liu YL, Breen K, Catchings A, Ranganathan M, Latham A, Goldfrank DJ, Grisham RN, Long Roche K, Frey MK, **Chi DS**, Abu-Rustum N, Aghajanian C, Offit K, Stadler ZK.Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. *JCO Oncol Pract*. 2021 Sep 28;OP2100382. doi: 10.1200/OP.21.00382. Online ahead of print.PMID: 34582274
63. Moukarzel LA, **Chi DS** Posterior pelvic exenteration, a crucial component in the surgeon's toolbox for optimizing surgical cytoreduction for advanced ovarian cancer. *J Gynecol Oncol*. 2022 May;33(3):e41. doi: 10.3802/jgo.2022.33.e41. Epub 2022 Feb 21.PMID: 35320890
64. Finch L, **Chi DS**. An overview of the current debate between using minimally invasive surgery versus laparotomy for interval cytoreductive surgery in epithelial ovarian cancer.

- J Gynecol Oncol. 2023 Sep;34(5):e84. doi: 10.3802/jgo.2023.34.e84. Epub 2023 Jul 26.PMID: 37545363
65. Jurado M, Chiva L, Tinelli G, Alcazar JL, **Chi DS**.The role of oncovascular surgery in gynecologic oncology surgery. Int J Gynecol Cancer. 2022 Apr 4;32(4):553-559. doi: 10.1136/ijgc-2021-003129.PMID: 35022310
 66. Sassine D, Liu C, Sonoda Y, **Chi DS** Safety and Efficacy of Supradiaphragmatic Lymph Node Dissection in Advanced Ovarian Cancer. J Gynecol Surg. 2022 Jun 1;38(3):202-206. doi: 10.1089/gyn.2022.0030. Epub 2022 Jun 13.PMID: 35785108
 67. Kahn RM, Chang SJ, **Chi DS**..Extra-abdominal cytoreductive techniques in ovarian cancer: how far can (should) we go? Int J Gynecol Cancer. 2024 Mar 4;34(3):379-385. doi: 10.1136/ijgc-2023-004630.PMID: 38438179
 68. Casanova J, Filipe Cunha J, Proença S, Chi D. "Mesenteric stripping using a Veress needle: A creative approach to resect small bowel disease in advanced ovarian cancer". Gynecol Oncol Rep. 2022 Dec 9;45:101111. doi: 10.1016/j.gore.2022.101111. eCollection 2023 Feb.PMID: 36703706
 69. Finch L, Muhammad DA, Chi DS.Cholecystectomy at the time of open cytoreductive surgery for ovarian cancer.Gynecol Oncol Rep. 2024 Mar 23;53:101369. doi: 10.1016/j.gore.2024.101369. eCollection 2024 Jun.PMID: 38584805
 70. Erfani H, Chiang S, Dickinson S, **Chi DS**, Kim SH.When it's not ovarian cancer: A case of a massive leiomyoma with hydropic change. Gynecol Oncol Rep. 2024 May 11;53:101415. PMID: PMC11126525.
 71. da Costa AG, Albergaria D, Almeida J, Nave M, Oliveira J, Catarino A, **Chi DS**, Casanova J.J Application of three-dimensional imaging software to map carcinomatosis in recurrent ovarian cancer. Surg Case Rep. 2024 Apr 1;2024(4):rjae188. doi: 10.1093/jscr/rjae188. eCollection 2024 Apr.PMID: 38572284
 72. Sia TY, Yaari Z, Feiner R, Smith E, Da Cruz Paula A, Selenica P, Doddi S, **Chi DS**, Abu-Rustum NR, Levine DA, Weigelt B, Fleisher M, Ramanathan LV, Heller DA, Long Roche K.Uterine washings as a novel method for early detection of ovarian cancer: Trials and tribulations. Gynecol Oncol Rep. 2024 Feb 3;51:101330. doi: 10.1016/j.gore.2024.101330.

Editorials and Clinical Commentaries:

1. **Chi DS**. Might this 25-year-old woman have uterine or ovarian cancer? [Cancer Consultation] Oncology News International 1999;8:7.

2. **Chi DS.** Patients with epithelial ovarian cancer need predictive models for surgical outcome and appropriate oncologic care. [Editorial Comment] *Abstracts in Hematology & Oncology* 2001;4(1):8.
3. **Chi DS.** Comparing systematic lymphadenectomy with resection of bulky nodes in women with optimally debulked advanced ovarian cancer. [Editorial Comment] *Abstracts in Hematology & Oncology* 2005;8(4):9-10.
4. **Chi DS, Barakat RR.** Aggressive surgery and ovarian cancer. [Correspondence] *J Clin Oncol* 2006;24(15):2395.
5. Eisenhauer EL, **Chi DS.** Prognostic importance of “normal” CA-125 levels prior to consolidation chemotherapy in advanced ovarian cancer. [Clinical Commentary] *Am J Hematol/Oncol* 2006;5(8):503-506.
6. Markman M, Sehouli J, Levenbach CF, **Chi DS.** Epithelial Ovarian Cancer: Focus on Targeted Therapy. [Editorial] *J Oncol.* 2010; 2010: 171425.
7. **Chi DS, Bristow RE, Armstrong DK, Karlan BY.** Is the easier way ever the better way? *J Clin Oncol.* 2011;29(31):4073-5.
8. Cliby W, Aletti G, **Chi D, Bristow R.** Re: Defining the limits of radical cytoreductive surgery in ovarian cancer. *Gynecol Oncol* 2012;125:509-510.
9. Naik R, Spirtos N, Pomel C, Bristow R, **Chi D, Vergote I, Donovan J.** The “definitive” trial of surgical cytoreduction in advanced-stage ovarian cancer. *Int J Gynecol Cancer* 2013;23(4):588-591.
10. Aletti GD, Bristow RE, **Chi D, Cliby WA.** There Is Nothing New Under the Sun. *J Clin Oncol.* 2015 Oct 20;33(30):3520. doi: 10.1200/JCO.2015.61.9536. Epub 2015 Aug 24.
11. Filippova OT, **Chi DS.** The Unyielding Fight Against the Premature Death of Patients With Advanced-Stage Ovarian Cancer. *Obstet Gynecol.* 2018 Sep;132(3):541-544. doi: 10.1097/AOG.0000000000002883. PMID: 30095758
12. Eisenhauer EL, **Chi DS.** Ovarian Cancer Surgery - Heed This LION's Roar. *N Engl J Med.* 2019 Feb 28;380(9):871-873. doi: 10.1056/NEJMe1900044. PMID: 30811915
13. Long Roche K, **Chi DS.** Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward...or too much risk? *Gynecol Oncol.* 2020 Jun;157(3):561-562. doi: 10.1016/j.ygyno.2020.05.003. PMID: 32527446

14. Hoffman MS, **Chi DS**, Clarke-Pearson DL, Cliby W, Creasman W, Underwood PB Jr. Surgical training in gynecologic oncology: Past, present, future. Gynecol Oncol. 2020 Jul;158(1):188-193. doi: 10.1016/j.ygyno.2020.05.006. Epub 2020 May 23. PMID: 32456991
15. Gardner GJ, **Chi DS**. Recurrent Ovarian Cancer - Sculpting a Promising Future with Surgery. N Engl J Med. 2021 Dec 2;385(23):2187-2188. doi: 10.1056/NEJMe2116353. PMID: 34874635

Date:

Signature: